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Chapter 1  
 
Introduction to Mutations in the DGC Causing Muscle Disease 
 
The Components and Structure of the DGC 
The dystrophin-glycoprotein complex (DGC) is a large multi-member 
complex with high expression and conservation located at the sarcolemma of 
cardiac, skeletal, and smooth muscle cells. The DGC is composed of both 
membrane bound, and membrane associated proteins. Two of the most highly 
conserved members of the DGC are the dystroglycans. These two proteins are 
transcribed from a single gene and are proteolytically cleaved to create α and β 
dystroglycan1-7. Alpha dystroglycan (αDG) is made up of two large globular 
domains connected via a long stalk8-11, that is proteolytically cleaved in the N-
terminal domain after translocation to the plasma membrane12. Alpha-
dystroglycan undergoes complex glycosylation that is required for its function as 
an extracellular matrix receptor12-16. The carboxyl-terminal domain of αDG binds 
the amino-terminal of β-dystroglycan (βDG) on the extracellular side of the 
sarcolemma17, 18. Beta dystroglycan is a single pass type-I transmembrane 
protein and is an integral component to the core of the DGC. The carboxyl-
terminal domain of βDG binds directly to multiple domain sites of the dystrophin 
or utrophin within the cytosol19-24.  
Dystrophin is a large 427-kD protein made up of four domains: the 
carboxyl-terminus domain, cysteine-rich domain, rod domain, and amino-
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terminus domain25. The dystrophin protein binds cystoskeletal F-actin26-28 with a 
tight stoichiometry of 24 actin monomers polymerized and bound laterally to the 
dystrophin protein at the amino-terminus and a number of spectrin repeats within 
the rod domain at a length of 65 nm29-32. The cysteine-rich domain of dystrophin 
binds to the carboxyl terminus of β-dystroglycan21 establishing a linkage between 
the cytoskeleton of muscle cells to the membrane bound portion of the DGC and 
thus the laminin-containing extracellular matrix through the linkage to αDG which 
is a high affinity laiminin receptor. Additionally α-syntrophin33, 34 and α-
dystrobrevin35 bind at the carboxyl-terminus of dystrophin and serve as 
accessory proteins that may help link signaling molecules to the DGC.   
In addition to dystrophin and the dystroglycans the DGC is composed of at 
least 5 other membrane-bound proteins, the sarcoglycans and sarcospan. 
Sarcospan is a quadruple-pass transmembrane protein of the tetraspanin 
superfamily. The interaction of sarcospan with the other members of the DGC 
appears to be indirect but appears important for expression of dystrophin and 
utrophin36. The sarcoglycans exist within the DGC as a tetrameric subcomplex of 
proteins. There have been six sarcoglycans identified and all are transcribed 
from different genes: alpa-sarcoglycan37 (αSG), beta-sarcoglycan38, 39 (βSG), 
gamma-sarcoglycan40 (γSG), delta-sarcoglycan41 (δSG), epsilon-sarcoglycan42 
(εSG), and zeta-sarcoglycan43 (ζSG). Together the sarcoglycan complex, 
dystroglycans, sarcospan, dystrophin, and syntrophins form the DGC, a large 
complex that appears to serve as an important link between the cytoskeleton and 
the basement membrane around muscle cells. 
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The Function of the DGC in Muscle 
The critical roles of the DGC in muscle are still debated but the DGC has 
been implicated in a number of cellular functions within muscle. The DGC has a 
proposed role in cellular signaling that is actively pursued but many conflicting 
reports have arisen that call into question whether the DGC truly plays a role in 
active signaling. Some of the earliest evidence suggesting a signaling role for the 
DGC was the fact that neuronal nitric oxide synthase (nNOS) copurifies with the 
DGC from skeletal muscle.44 Neuronal nitric oxide synthase has a role in cardiac 
myocyte contraction45, calcium cycling46, 47, and left ventricular function48. The 
primary nNOS signaling mechanism in cardiac myocytes is through 
phosphorylation of phospholamban causing increased calcium uptake into the 
sarcoplasmic reticulum49, 50. Neuronal nitric oxide synthase is associated with the 
DGC through tight binding with α1-syntrophin and the PDZ domain of α1-
syntrophin binds dystrophin51. Originally the association of nNOS with the DGC 
led to the hypothesis that knockout would cause a dystrophic phenotype similar 
to that seen in many other mutations of the DGC. However, knockout of nNOS 
does not cause a noticeable muscular dystrophy52 nor does knockout of α1-
syntrophin53, β2-syntrophin or both α1 and β2-syntrophin54. Although alteration of 
the nNOS-syntrophin complex within the DGC does not cause muscular 
dystrophy disruption of nNOS does appear to alter other pathways such as 
muscle regeneration55 and muscle inflammation56. Despite association with the 
DGC and the role of nNOS in muscle signaling pathways, exactly how the DGC 
regulates action of nNOS is currently unknown.  
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In addition to signaling pathways involving nNOS it is proposed that β-
dystroglycan (βDG) has a direct signaling role through the binding of the adaptor 
protein growth factor receptor 2 (Grb-2). Cells bind extracellular matrix proteins, 
including laminin-α2, triggering phosphorylation directly on tyrosine residue 892 
of βDG that binds the SH3 domain of Grb-257, a protein involved in the 
organization of the cytoskeleton. Oddly this site is also where βDG binds to 
dystrophin suggesting that phosphorylation at this site in βDG may somehow 
cycle the interaction of βDG with either Grb2 or dystrophin. Preventing 
phosphorylation of βDG improves the dystrophic phenotype of dystrophin 
deficient mice58 further supporting the hypothesis dystrophin binding to βDG 
helps stabilize the complex. 
There is quite a bit of evidence suggesting that the DGC is not only 
involved in cell signaling but is also partially responsibly for stabilizing the 
sarcolemma during mechanical strain (Figure 1-2). The dystrophin protein and 
thus DGC is enriched at the costamere aligning to the z-discs in skeletal 
muscle59, 60. The costameres are hypothesized to be partially responsible for 
lateral force transmission in both skeletal muscle61 and cardiac muscle62 
suggesting that the DGC plays some role in force transmission and perhaps 
protection of the sarcolemma during mechanical events. Sarcolemma membrane 
stability is decreased when dystrophin is lost in patients63, mouse muscle64, 65, or 
cultured mouse myotubes66. Additionally, knockout of dystroglycan67 results in 
compromised sarcolemmal permeability. When membrane stability is altered the 
sarcolemma becomes increasingly permeable to extracellular ions including 
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calcium65, 66, 68, 69 and this phenotype is further exacerbated through exercise and 
activation of the muscle70 but can be improved through immobilization71, 72 
indicating that the mechanical action of muscle stretch and contraction is at least 
partially responsible for sarcolemmal damage that occurs in muscle with 
disrupted DGC.  
 
Mutations in the DGC and Related Diseases 
 The importance of the DGC in muscle is indicated by the fact that 
mutations in many of its components lead to inherited forms of muscle disease. 
There have been many mutations identified within the genes responsible for 
transcoding the proteins of the DGC and within genes responsible for some 
modulations of the DGC. Most well known are mutations within the dystrophin 
gene that cause Duchenne muscular dystrophy73, 74 (DMD) or less severe Becker 
Muscular Dystrophy25 (BMD). DMD/BMD are X-linked disorders, DMD affects 1 
in 3500 live male births and is characterized by severe skeletal muscle wasting 
and weakening leading ultimately to loss of ambulation and early death. In 
conjunction with severe skeletal phenotypes individuals with DMD are at a high 
risk for cardiovascular complications including progressive dilated 
cardiomyopathy (DCM), congestive heart failure (CHF), arrhythmias, and sudden 
cardiac death75. BMD affects approximately 1 in 19,000 live male births and 
results in a similar, but much less severe phenotype than that of DMD. Mutations 
in the dystrophin gene cause a total loss of the dystrophin protein76-78 (DMD) or a 
reduction of dystrophin protein79 (BMD) at the plasma membrane in muscle. 
!
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 Despite the integral role played by α and βDG in overall DGC function only 
one disease causing mutation has been identified in the gene that codes for the 
two proteins. A T192M mutation in a single patient was identified that presented 
with limb-girdle muscular dystrophy and cognitive impairment80. This mutation 
results in hypoglycosylation of αDG and a decrease in laminin-binding activity. 
This primary dystroglycanopathy actually resembles a number of other mutations 
that have been identified in genes responsible for post-translational modification 
of αDG that are pathogenic resulting in several forms of mild to severe muscular 
dystrophies. Glycosyltranferases are enzymes responsible for imparting sugar 
moieties to proteins. There are eight known glycosyltransferases necessary for 
proper glycosylation of αDG: POMT1, POMT2, POMGnT1, LARGE, FKRP, 
IPSD. Mutations in many of these glycosyltransferases is sufficient to disrupt 
normal binding of αDG to laminin-α2 causing a dystrophic phenotype81-87.  
 The majority of mutations in the DGC causing muscle disease all have a 
common theme – disruption of the functional linkage between the cytoskeleton in 
muscle and the extracellular matrix through the DGC. Two connections are 
responsible for this DGC protection during mechanical events: 1) The link to the 
extracellular matrix via glycosylated αDG and 2) the link to the cytoskeleton via 
dystrophin. If either of these two links is disturbed it results in a mild to severe 
muscular dystrophy and a greater prevalence for cardiac disease suggesting the 
role of mechanical protection by the DGC is similar in both skeletal and cardiac 




The Sarcoglycans are Integral Components of the DGC 
 The sarcoglycan complex is a specific subcomplex of four sarcoglycans 
that exists at the plasma membrane and associated with the DGC. There have 
been six sarcoglycan genes identified and each transcodes a separate 
sarcoglycan protein. There have been a number of mutations identified within the 
sarcoglycans. The most common mutations are those in the sarcoglycans 
expressed in striated muscle that cause limb-girdle muscular dystrophy. 
Examining the literature on these sarcoglycans individually allows insight into the 
role that a single sarcoglycan may play within the complex as a whole.  
Alpha-sarcoglycan 
 Alpha sarcoglycan (αSG), originally named adhalin, is a 50-kD member of 
the sarcoglycan complex37, 88, 89. αSG is expressed highly in skeletal muscle and 
in lower levels in cardiac muscle. The cardiac form of αSG is a shorter 
alternatively spliced form of the same αSG gene product90. αSG is single-pass 
type-I transmembrane protein composed of three primary domains: a large 
extracellular domain, transmembrane domain, and a cytoplasmic domain. αSG 
contains two putative sites for N-linked glycosylation at residues 174 and 246 
and is glycosylated in vivo91 in skeletal muscle.  
 Alpha sarcoglycan is transcoded by the SGCA gene located on 
chromosome 17. There have been at least 28 naturally occurring variants and 
mutations identified in αSG and many of these mutations in the SGCA gene 
cause limb-girdle muscular dystrophy type 2D (LGMD2D) of differing severity89, 
92-95. Interestingly, all of the known LGMD2D occur within the αSG’s extracellular 
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domain. The bulk of the αSG protein is the extracellular domain and contains a 
cadherin-like domain from residues 27-13196. This domain has been 
hypothesized to be important for interactions between the cadherin-like domain 
within αDG. Additionally, it is possible that the cadherin-like domain within αSG 
may be important for interaction with other sarcoglycans or adhesion to 
unidentified binding partners within the extracellular matrix. The potential for the 
cadherin-like domain to bind proteins within the ECM is even more intriguing 
when it is noted that 16 of the known mutations causing LGMD2D map to this 
domain in αSG. However, there are at least another 12 LGMD2D causing 
mutations within αSG that map to the extracellular domain but not within the 
cadherin-like domain. It is possible that mutations outside the cadherin-like 
domain may still alter protein structure enough to disrupt αSG stability sufficient 
to cause loss of the protein and subsequent muscular dystrophy. Limb-girdle 
muscular dystrophy 2D causing mutations in αSG likely affect protein stability 
resulting in protein loss from the sarcolemma. It is likely that mutations within the 
extracellular domain of αSG exert their effects by disrupting interactions of αSG 
with the other sarcoglycans leading to degradation of αSG through endoplasmic 
reticulum associated degradation (ERAD).  
 A mouse model of LGMD2D has been generated in which the Sgca gene 
has been knocked out. This mouse recapitulates the degenerative skeletal 
muscle phenotype seen in patients with LGMD2D97. Similar to LGMD2D patients 
these mice show no apparent cardiac muscle defects. This is likely due to 
compensation by εSG in cardiac tissue. εSG is expressed at lower levels in the 
!
! 9!
skeletal and cardiac muscle and in high levels in smooth muscle98, 99. 
Overexpression of εSG in striated muscle of mice lacking αSG ameliorates 
skeletal muscle dystrophy100 supporting the hypothesis of εSG compensation in 
αSG deficiency. Furthermore, double knockout of α and εSG in mice results in 
cardiac fibrosis and increased membrane permeability exacerbated by 
exercise101.  
Beta-sarcoglycan 
Beta sarcoglycan (βSG) is a 43-kD member of the sarcoglycan complex 
highly expressed in both skeletal and cardiac muscle38, 39, 102-105. βSG is a single-
pass type II transmembrane protein composed primarily of three domains: a 
cytoplasmic domain, a transmembrane domain, and an extracellular domain. 
βSG contains a putative N-linked glycosylation site at residue 258 and two known 
glycosylation sites at 158 and 211106. It should be noted that experimental 
evidence identifying the two known N-linked glycosylation residues, 158 and 211, 
was only demonstrated in human liver; the precise glycosylation of βSG in 
muscle is still undetermined. Additionally, sequence analysis reveals possible 
sites for disulfide bonds in βSG between residues 288 and 314, and between 290 
and 307.  
βSG is transcoded by the SGCB gene located on chromosome 4. There 
have been at least 13 naturally occurring variants and mutations identified in 
βSG, and many of the mutations in the SGCB gene cause limb-girdle muscular 
dystrophy type 2E38, 39, 94, 107-109 (LGMD2E). Only one of the identified mutations 
in βSG occurs within its cytoplasmic domain. A glutamine to glutamic acid 
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substitution at residue 13 in the cystoplasmic domain causes severe DMD-like 
LGMD2E. It is unclear what the functional consequences of this transformation 
are but this particular mutation and subsequent LGMD2E supports the 
hypothesis that the δ/β sarcoglycan core interacts directly with dystrophin110 
within the cytoplasmic domain of βSG. The remaining mutations in βSG occur 
within the extracellular domain and likely disrupt formation of the δ/β sarcoglycan 
core resulting in complete sarcoglycan complex loss. Oddly despite a large 
extracellular domain, residues 87-314, all known disease causing mutations fall 
between residues 91 and 184. This may be because mutations outside of this 
region of the extracellular domain do not disrupt βSG protein interactions 
resulting in loss of protein and thus do not cause disease. A mouse model of 
LGMD2E has been generated in which the Sgcb gene has been knocked out. 
These mice develop severe muscular dystrophy and cardiomyopathy111. This 
phenotype is remarkably similar to patients with LGMD2E although global 
muscular dystrophy in these mice is more severe than that seen in patients 
suggesting that pathology in humans differs slightly from those in mice.   
Gamma-sarcoglycan 
 Gamma sarcoglycan (γSG) is 35-kD member of the sarcoglycan complex 
highly expressed in both skeletal and cardiac muscle40. γSG is a single-pass type 
II transmembrane protein composed primarily of three domains: a cytoplasmic 
domain, transmembrane domain, and extracellular domain. γSG contains one 
putative site for N-linked glycosylation at residue 110. Additionally, sequence 
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analysis reveals possible sites for disulfide bonds in γSG between residues 265 
and 290, and between residues 267 and 283.  
 γSG is transcoded by the SGCG gene located on chromosome 13. There 
have been at least 5 naturally occurring variants and mutations identified in γSG 
and many of the mutations in the SGCG gene cause limb-girdle muscular 
dystrophy type 2C40, 112-115. All but one mutation identified in γSG occurs within 
the extracellular domain. Point mutations in this domain and truncations lacking 
the C-terminus likely disrupt formation of the sarcoglycan complex. Oddly a 
leucine to proline mutation has been identified at residue 53 within the 
transmembrane domain of γSG112. This mutation causes mild LGMD2C, and 
although the sarcoglycans were reduced in muscle biopsies they are still present 
at higher levels than more severe limb-girdle muscular dystrophies. Mutations 
within the extracellular domain of γSG probably disrupt interaction with the δ/β 
sarcoglycan core and full sarcoglycan complex assembly. The L53P mutation 
within the transmembrane domain of γSG likely disturbs sarcoglycan complex 
integration into the plasma membrane explaining why the sarcoglycans are 
present but reduced at the plasma membrane. A mouse model of LGMD2C has 
been generated in which the Sgcg gene has been knocked out. These mice 
develop muscular dystrophy, cardiomyopathy, and smooth muscle necrosis91.  
Delta-sarcoglycan 
 Delta sarcoglycan (δSG) is a 35-kD member of the sarcoglycan complex 
highly expressed in skeletal and cardiac muscle41, 116. δSG is a single-pass type 
II transmembrane protein composed primarily of three domains: a cytoplasmic 
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domain, transmembrane domain, and large extracellular domain. δSG contains 
three putative sites for N-linked glycosylation at residues 60, 108, and 284. 
Additionally sequence analysis reveals possible sites for disulfide bonds between 
residues 263 and 288, and between 265 and 281. δSG is also phosphorylated at 
serine residue 194, and threonine residue 196 in human platelets117. There have 
been at least 8 naturally occurring variants and mutations identified in δSG 
leading to limb-girdle muscular dystrophy 2F and/or cardiomyopathy. Mutations 
and natural variants of δSG are discussed in further detail in the section, 
“Mutations in Delta Sarcoglycan and Related Diseases.”  
Epsilon-sarcoglycan 
Epsilon sarcoglycan (εSG) is a 45-kD member of the sarcoglycan complex 
ubiquitously expressed in human tissue42. Although εSG is ubiquitously 
expressed it is lower in overall abundance than α, β, γ, and δSG.  εSG is a single-
pass type I transmembrane protein composed primarily of three domains: a 
cytoplasmic domain, transmembrane domain, and large extracellular domain. 
Residue 200 in εSG is a site of N-linked glycosylation within liver tissue106.  
εSG is transcoded by the SGCE gene on chromosome 7. There have 
been at least 15 naturally occurring variants and mutations identified in εSG and 
many of the mutations in the SGCE gene cause myoclonus dystonia118-126 
(DYT11). Myoclonus dystonia disorders are heterogeneous in presentation but 
generally are characterized by involuntary jerks of the arms, neck, and trunk. 
Additionally, patients frequently develop psychological abnormalities. The 
molecular basis for myoclonus dystonia is still not well understood but patients 
!
! 13!
exhibit abnormal EEG in the subcortical region of the brain suggesting DYT11 is 
neurological in regard to pathology124. It is unclear why mutations in εSG cause 
disease dissimilar to mutations in the other sarcoglycans but suggests the εSG 
has a functional role in brain that is clearly unique from the role that the 
sarcoglycan complex plays in striated muscle.    
Zeta-sarcoglycan 
Zeta sarcoglycan (ζSG) is a 40-kD member of the sarcoglycan complex 
expressed primarily in striated muscle and highly in smooth muscle cells43. ζSG 
is a single-pass type II transmembrane protein composed primarily of three 
domains : a cytoplasmic domain, transmembrane domain, and extracellular 
domain. ζSG contains two putative glycosylation sites at residues 62 and 110. 
Additionally sequence analysis reveals possible sites for a disulfide bond 
between residues 273 and 289.  
 
Sarcoglycan Organization 
 Despite variation among the mutations, disease pathology among many of 
these mutations is remarkably similar. One explanation for this phenomenon is 
that many of the point mutations within single sarcoglycans are null mutations 
that completely destabilize the assembly of the sarcoglycan complex. The level 
of severity among the many mutations in the sarcoglycan complex may be 
completely related to the degree to which the sarcoglycan complex is 
destabilized. For instance, mutations within the extracellular domain of βSG 
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cause severe skeletal muscle dystrophy as well as cardiomyopathy, whereas 
mutations in αSG are not as severe. 
The six sarcoglycans vary in tissue expression. In cardiac and skeletal 
muscle the most highly expressed sarcgolycans are β, δ, γ, and α. The homology 
among a number of sarcoglycans suggests that the some of the sarcoglycans 
may have arisen from gene duplication events during vertebrate evolution. Global 
sequence alignments produce three distinct groups among the sarcoglycans. 
βSG is about one third homologous to three other sarcgolycans, but its homology 
is relatively low compared to the high homology among other sarcoglycans. The 
second group is the α/ε sarcoglycans. These two sarcoglycans are greater than 
50 percent homologous to one another and show very low homology with all 
other sarcoglycans. The third and final group is the γ/δ/ζ sarcoglycans.  These 
three sarcoglycans all have greater than 70 percent homology with each other 
and low homology with all other sarcoglycans. See table 1.2 for sarcoglycan 
protein family homology details.  
 Although the sarcoglycans show homology with one another each 
individual sarcoglycan in the complex is required for proper assembly and 
localization to the plasma membrane127. It is hypothesized within skeletal and 
cardiac muscle that the stoichiometry of the tetrameric sarcoglycan complex 
composed of α, β, γ, and δ is 1:1:1:1116, and that assembly of the sarcoglycans 
and subsequent association with sarcospan and the dystroglycans follows a strict 
process through the secretory pathway. The first step of sarcoglycan synthesis 
and assembly in muscle is the association of a sarcoglycan core composed of δ 
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and βSG128, 129. The second and third steps are not completely defined, but follow 
one of two likely scenarios. The first possible scenario is that γSG is added to the 
δ/β core and then associates directly with αSG. The second possible scenario is 
that αSG directly interacts with the δ/β core rather than being recruited to the 
complex by γSG91, 130, 131. Of all the interactions within the sarcoglycan complex, 
the association of α to the remaining sarcoglycans is the weakest, supporting the 
idea that it is added last and with the lowest overall binding affinity128 (Figure 1-
3). 
 Regardless of the remaining order the most essential step of sarcoglycan 
complex assembly is the association of the δ/β core130. Mutation or loss of δ, β, or 
both sarcoglycans disrupts complex assembly and localization to the plasma 
membrane is halted. If this occurs all sarcoglycan components are completely 
undetectable at the plasma membrane91, 111. Conversely, when γSG is lost there 
are still detectable, albeit reduced, levels of the other sarcoglycans at the plasma 
membrane in muscle91. Additionally, there are residual levels of δ, β, and γSG 
detectable in skeletal muscle when αSG is lost and the entire complex appears 
to be expressed normally in cardiac muscle97. This may be due to other 
sarcoglycans, including εSG, compensating for the mutation or loss of αSG. 
 Sarcoglycan compensation is observed in cardiac muscle where εSG can 
compensate for the loss of αSG97. The high homology between α and εSG is 
likely what allows compensation without noticeable deleterious effects. This 
hypothesis is further supported by the fact that mutations resulting in loss of βSG 
generally have no compensatory mechanism and there are no sarcoglycans with 
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high enough homology to replace βSG. However, mutations within δSG are 
particularly pathogenic and there is no apparent compensation by other 
sarcoglycans despite sharing high homology with γ and ζSG. This may be due to 
the crucial assembly of the δ/β sarcoglycan core and that no compensation can 
occur during this critical step of sarcoglycan complex assembly.  
 It is possible that the interaction of β and δ to form the sarcoglycan core 
may be the only necessary ordered step in sarcoglycan complex assembly, and 
that interaction of γ and αSG with the complex may occur in any manner 
thereafter. There is another possibility suggested by a handful of groups that δ, β, 
and γSG can also form a trimeric complex, distinct in function from the tetrameric 
complex110, 128, 132. The exact ordering of the sarcoglycan associations is still 
unclear, but what is known is that the initial interactions of the sarcoglycans occur 
within the ER where the complex is formed and then transported to the golgi and 
finally to the plasma membrane133. The sarcoglycans exit the golgi as a complex 
and are associated with sarcospan and the rest of the DGC either at the plasma 
membrane or at some point in the secretory pathway between the golgi and the 
plasma membrane133 (Figure 1-4).  
 
The Function of the Sarcoglycan Complex 
 The role of the sarcoglycan complex both in isolation and as a member of 
the DGC is not well defined. It is assumed that the sarcoglycan complex 
stabilizes the DGC at the plasma membrane in some manner. Loss of the 
sarcoglycan complex results in increased sensitivity of βDG to cleavage by a 
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matrix metalloproteinase (MMP) disrupting the linkage of the cytoskeleton to the 
extracellular matrix134-136. Muscular dystrophies that retain the sarcoglycan 
complex, like those caused by defects in glycosyltransferases, do not have 
similar cleavage of βDG135 suggesting that physical access to the cleavage site 
on βDG by the MMP may be necessary and the presence of the sarcoglycan 
complex inhibits this access136.  
 More evidence pointing toward a role in DGC stabilization is a strong 
association between the sarcoglycan complex and the dystroglycans and 
dystrophin protein24, 128, 137-139. It is unknown whether the sarcoglycan complex 
binds directly to αDG, βDG, or both but in muscle that has lost dystrophin at the 
membrane the sarcoglycan complex is drastically reduced140. Additionally, the C-
terminus of dystrophin appears to directly interact with δ and βSG in vitro in COS-
1 cells although this interaction is rather weak110. It is possible that in vivo 
dystrophin binds a fully assembled sarcoglycan complex with greater affinity. 
However, the association of dystrophin to the remaining members of the DGC is 
not contingent upon sarcoglycan expression because loss of the sarcoglycan 
complex results in only diminished expression of dystrophin at the plasma 
membrane97 or no change in dystrophin expression91, 111, 141. The apparent role of 
dystrophin in membrane stabilization63, 66, and the close association of the 
sarcoglycans with dystrophin, suggests that the role of the sarcoglycan complex 
in stabilization of the DGC also extends to a mechano-protective role. When the 
sarcoglycan complex is lost, cell membrane permeability is compromised91, 97, 141-
144. However, there is evidence to suggest that the exact mechanical role of the 
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sarcoglycan complex may be distinct from the role that dystrophin plays145. In 
addition to DGC stabilization, the sarcoglycan complex may have a direct role in 
linking the extracellular matrix to the cytoskeleton. Both γ and δSG interact with 
the actin binding protein γ-filamin146. On the extracellular side disruption of either 
α or γSG reduces cell adhesion mediated via α5β1 integrin147.  
  There is also data to suggest the sarcoglycan complex is involved in cell 
signaling pathways via the DGC. The sarcoglycan-sarcospan complex can 
associate directly with the N-Terminal region of the α-dystrobrevins147. Despite 
binding the dystrobrevins it has not been established that the sarcoglycans 
actually alter signaling activity. It may be that the sarcoglycans bind dystrobrevin 
and form a scaffold for signaling through dystrophin rather than directly modulate 
activity of the dystrobrevin-syntrophin-nNOS complex. The type-II sarcoglycans 
δ, β, and γ all contain epidermal growth factor (EGF) receptor-like domains in the 
C-terminus148 suggesting these sarcoglycans may be receptors for unknown 
signaling mechanisms. One sarcoglycan signaling mechanism that is known is 
phosphorylation of γSG and subsequent upregulation of the ERK signaling 
pathway following eccentric contractions in skeletal muscle149. The function of 
this phosphorylation is unknown but suggests that the sarcoglycan complex may 
act as a signaling sensor when muscle is mechanically stimulated. The 
sarcoglycan complex is also implicated in ATP signaling via 
αSG. Alpha sarcoglycan contains an ATP-binding site in the extracellular domain 
and hydrolyzes ATP150, 151. ATP signaling via this pathway appears protective for 
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myocytes during contraction152 suggesting that loss of this enzymatic function 
may play a role in muscular dystrophy pathology.  
 The sarcoglycan complex is implicated in diverse roles in cellular function, 
however parsing the exact role of each sarcoglycan is confounding for a number 
of reasons. 1) Organization of the sarcoglycan complex is contingent upon 
proper expression of all sarcoglycans. 2) Compensation that occurs between 
sarcoglycans in disease states is not complete and appears tissue specific. 3) 
Muscular dystrophies caused by mutations in the sarcoglycans have similar 
pathogenic outcomes suggesting the sarcoglycans may function primarily as a 
complex. Mutations in the sarcoglycans have so far provided the most insight into 
both the function of individual sarcoglycans and the sarcoglycan complex as a 
whole.   
 
Mutations in Delta Sarcoglycan and Related Diseases 
! Delta sarcoglycan is a crucial sarcoglycan that has not been discussed yet 
that is both critical for sarcoglycan complex formation and function and is also 
unique in the way mutations apparently affect pathology. Similar to mutations in 
α, β, and γSG recessively inherited mutations in δSG cause limb-girdle muscular 
dystrophy type 2F112, 116, 153-156 (LGMD2F). The original mutation linking δSG to 
LGMD2F was a deletion of nucleotide 656 in the coding region of the gene that 
produces a premature truncated protein lacking the C-terminus and cysteine rich 
region of the δSG protein156. A second LGMD2F patient was identified resulting 
from a truncated δSG protein154. This mutation, R165X, causes a severe 
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muscular dystrophy suggesting any number of mutations in δSG may cause 
LGMD2F. Since the initial discovery of δSG mutations leading to LGMD2F there 
have been at least three other mutations in δSG identified that cause LGMD2F of 
varying severity: E262K155, G76C112, and A131P153. Truncations of the δSG 
protein expressed in COS-1 cells have suggested that the region of the 
extracellular domain of δSG nearest the plasma membrane is the site of 
interaction with βSG110 during sarcoglycan complex assembly. All five known 
mutations that cause LGMD2F occur within the extracellular domain of δSG 
supporting the hypothesis that this region is critical for δSG function. 
 In addition to causing LGMD2F some mutations in δSG have been linked 
to dilated cardiomyopathy (DCM) without an accompanying skeletal muscle 
dystrophy. Using candidate gene screening, patients with a dominant familial 
pattern of DCM inheritance were identified that had mutations within δSG157, 158. 
One mutation identified was a deletion of lysine residue 238 (ΔK238). Following 
heart transplant of the patient immunostaining of the affected myocardium 
showed a reduction, but not complete loss of the sarcoglycan complex at the 
plasma membrane. It was not identified whether the other DCM-linked δSG 
mutations followed a similar pattern of expression within the myocardium. 
Transgenic mice overexpressing DCM-linked δSG mutant S151A develop DCM 
and have a subsequent early mortality. Oddly δSG mutant S151A proteins did 
not localize to the plasma membrane and were instead retained in discrete 
nuclear foci costained with nuclear proteins lamin A/C and emerin159. Additionally 
nuclear foci stained with mutant δSG S151A show partial staining for β and γSG. 
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These results suggested that S151A is a dominant negative mutant affecting 
trafficking and not necessarily sarcoglycan complex assembly or function. The 
S151A mutation does not appear to follow the same pattern of expression as 
ΔK238 further confounding the debate about whether DCM-linked mutations in 
δSG are the result of a dominant negative effect or haploinsufficiency. A report of 
a consanguineous family expressing both an LGMD2F causing mutation (A131P) 
and DCM-linked S151A mutation in δSG showed that individuals with both 
mutations develop LGMD2F but not DCM153 calls into question whether the 
S151A mutation in δSG actually causes DCM. The heterogeneous presentation 
of DCM causing mutations in δSG raises an important question about the 
mechanism of pathology. Dominantly inherited mutations do not appear to act as 
null mutations leading to the hypothesis that either these mutants act as 
dominant negative proteins or haploinsufficiency causes disease progression.  
 
The Structure of Delta Sarcoglycan 
 The native structure of δSG has not been completely elucidated. Delta 
sarcoglycan possesses a short cytosolic tail at the N-terminus from residues 1-
35. A hydrophobic region from residues 36-56, likely forming an α-helix (based 
on sequence analysis), comprises the transmembrane domain. Finally, the 
majority of the δSG protein is the extracellular domain from resides 57-289. The 
extracellular domain contains a conserved cysteine rich motif in its final 30 
residues prior to the C-terminus. Deletion of the protein prior to the cysteine rich 
motif results in drastic reduction of the sarcoglycan complex at the plasma 
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membrane suggesting this region of the protein and particular motif are 
necessary for proper localization following secretory pathway processing110. The 
residues in the extracellular domain between 57 and 92 appear necessary for the 
interaction with βSG to form the δ/β sarcoglycan core110. This region of the 
sarcoglycan protein contains one of the sites of putative N-linked glycosylation 
although the role of glycosylation for the interaction with the sarcoglycan complex 
or proper processing through the secretory pathway is unclear. Finally the 
intracellular tail of δSG appears to interact directly with the C-terminus of 
dystrophin139 however this interaction only occurs when δ and βSG are 
associated110 suggesting that not only is the δ/β sarcoglycan core essential for 
complex assembly but also for some functional linkage to the cytoskeleton via 
dystrophin. The δSG protein forms multiple interactions with members of the 
DGC. What is not completely clear is how the post-translational modifications of 
δSG affect these interactions and or the function of δSG.  
 The sarcoglycan complex appears to operate as a unit. Mutations and/or 
loss of any one sarcoglycan normally expressed in muscle destabilizes the entire 
complex causing muscular dystrophy and commonly cardiomyopathy. There is 
some evidence to suggest that despite the sarcoglycan complex operating as “a 
unit” some sarcoglycans have singular functions as well. The role of αSG in cell 
signaling, and the intracellular connection established between δ/β sarcoglycan 
and the protein dystrophin suggests that, much like the DGC as a whole, the 
sarcoglycan complex forms many interactions via the various sarcoglycan 
proteins. Most intriguing is the ability of δSG mutations R97Q and R71T to 
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behave differently than mutations already identified that cause limb-girdle 
muscular dystrophy 2F. This in addition to the apparent dominant pattern of 
inheritance suggests that the mechanism of δSG dysfunction is unique among 
sarcoglycan mutations. Oddly disease causing mutations in δSG all occur within 
the extracellular domain suggesting that this region and its post-translational 
modifications are essential for proper function of the δSG protein. Additionally, 
how different mutations in δSG present with entirely different disease pathology 
has not been addressed. The lack of disease pathology in skeletal muscle 
caused by DCM-linked mutations in δSG suggests that these mutations either 
cause haploinsufficiency in cardiac tissue or act as dominant negative proteins 
when integrated into the sarcoglycan complex.  
 
Rationale and Experimental Approach 
 One of the most complex issues concerning δSG is that mutations 
normally result in the destablization of the entire sarcoglycan complex. The 
molecular mechanisms for the subsequent development of muscular dystrophy 
and cardiomyopathy are confounding because of this. The identification of 
dominantly inherited mutations in δSG linked to DCM suggests that some 
mutations in δSG may exert their effect in a dominant negative manner on 
sarcoglycan complex function. Why these mutations result in only 
cardiomyopathy and no skeletal muscle dystrophy is a mystery. Additionally the 
extracellular domain of δSG appears to be the region of the protein most 
necessary for δSG interactions and cellular function. Not by coincidence this 
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region of the protein undergoes heavy post-translational modifications suggesting 
that, similar to glycosylation of αDG, the post-translational modifications of δSG 
likely have functional roles beyond simple processing through the secretory 
pathway.  
 The overall working hypothesis of this dissertation is the following: 
dominant mutations in the extracellular domain of delta sarcoglycan alter 
protein structure or post-translational modifications causing DGC 
dysfunction and lead to disrupted mechanical stability of cardiac 
myocytes. This hypothesis was tested with the following specific aims: 
Specific Aim 1) Determine if sarcolemmal integrity is impaired in cardiac 
myocytes expressing DCM mutant δSG proteins.  
 The purpose of this set of experiments, described in Chapter 2, was to 
investigate functional defects of cardiac myocytes caused by DCM mutant δSG. 
The model for this study was isolated rat cardiac myocytes transduced with 
adenoviral vectors expressing wild type or mutant δSG R97Q or R71T driven by 
the CMV promoter and engineered with a C-terminus myc tag. I tested the 
hypothesis that DCM-linked δSG mutant proteins act in a dominant negative 
manner to destabilize sarcolemmal integrity in cardiac myocytes. Using a live 
cell-labeling assay shows that mutant δSG proteins localize and integrate into the 
plasma membrane with the same efficiency as wild type proteins suggesting that 
the mechanism for mutant pathology is not the same as LGMD2F. In order to test 
sarcolemmal integrity cardiac myocytes were incubated with the membrane 
impermeable dye propidium iodide and stretched for 24 hours in a physiological 
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range. After mechanical strain cardiac myocytes expressing mutant δSG R97Q 
or R71T have increased dye uptake indicating that expression of mutant δSG is 
sufficient to cause sarcolemmal instability. Additionally cardiac myocytes 
expressing mutant δSG show an increase in cell contracture post-stretch that 
suggests plasma membrane integrity is compromised enough to alter cell 
morphology. Furthermore, cell rounding may actually be an indication of 
increased cell death in a population of cardiac myocytes expressing mutant δSG. 
Unexpectedly cardiac myocytes expressing mutant R71T display an abnormal 
expression pattern when observed via western blot. Exposure of mutant δSG 
R71T to endoglycosidase EndoH or PNGaseF reveals this abnormal expression 
to be aberrant glycosylation. This was not expected but is easily explained. The 
alteration of residue 71 from an arginine to a threonine creates an ectopic 
consensus site for N-linked glycosylation. This study demonstrates that DCM-
linked δSG mutants act in a dominant negative manner to destabilize the 
sarcolemma during mechanical strain. Additionally these results suggest a 
functional role for post-translational modifications of the extracellular domain of 
δSG 
Specific Aim 2) Determine if glycan residues on δSG are necessary to stabilize 
the sarcolemma during mechanical strain.  
 To further identify the functional role of N-linked glycosylation in δSG 
protein function adenovirus was generated expressing mutant δSG lacking the 
putative glycosylation consensus sites at residue 60, 108, and 284. I tested the 
hypothesis that glycan residues on the δSG protein are necessary for protein 
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function and stabilize δSG protein interactions within the DGC. These results, 
described in Chapter 3, demonstrate that the only residues glycosylated on δSG 
in cardiac myocytes are residue 108 and 284. Oddly residue 108 appears to be 
glycoylated on all δSG proteins whereas residue 284 appears to be occupied on 
approximately half of the proteins based on western blot visualization. Loss of 
glycosylation at either site does not affect δSG localization to the plasma 
membrane as previously suspected. To test whether these glycan residues are 
necessary for sarcolemmal stabilization cardiac myocytes expressing glycan 
deficient δSG were submitted to mechanical strain. Mutant N108Q expressing 
cardiac myocytes detach from the laminin coated plate after mechanical strain. 
Together these results suggest that the glycan at residue 108 is necessary for 
DGC interactions with the extracellular matrix during mechanical strain.  
 Chapter 4 will summarize the findings of this dissertation and explain how 
these results fit into current understanding of DGC dysfunction and the functional 
role δSG plays in the overall DGC in cardiac myocytes. Finally, this dissertation 
will conclude with unanswered questions and logical future directions to answer 
these questions. Ultimately a better understanding of the functional role of δSG 
within the DGC will hopefully provide insight into therapeutic targets for patients 
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Figure 1-1 Composition of the DGC in striated muscle. Membrane bound 
proteins are the dystroglycans, sarcoglycans, and sarcospan. The dystroglycans 
and sarcoglycans undergo heavy post-translational modifications in the form of O 
and N-linked glycosylation. Glycan residues on αDG are necessary for binding to 
laminin. Singaling is accomplished primarily through nNOS and the syntrophin 
complex (α1 and β1) that interacts directly with dystrophin. Sarcolemma 






Figure 1-2 The DGC acts as a functional linkage between the basal lamina 
and myofilaments in striated muscle. This linkage stabilizes the sarcolemma 





Figure 1-3 Assembly of the sarcoglycan complex in the secretory pathway. 
The sarcoglycans are first synthesized in the ER and N-glycosylated. 
Sarcoglycan complex assembly then occurs in multiple steps in the endoplasmic 
reticulum. 1) δ and βSG associate to form the δ/β sarcoglycan core. 2) Either γSG 
or αSG is recruited to the δ/β sarcoglycan core. 3) The final sarcoglycan either α 
or γ is recruited to and associates with the intermediate tricomplex to form the full 
sarcoglycan complex. Full sarcoglycan assembly is normally a prerequisite for 
continued processing through the secretory pathway to the golgi apparatus. 
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Figure 1-4. Overall assembly & post-translational modifications of the DGC 
A, The primary membrane bound portion of the DGC is synthesized in the 
endoplasmic reticulum. The sarcoglycans are N-glycosylated in the ER and 
assemble to form the sarcoglycan complex. The dystroglycans are N-
glycosylated in the ER. Sarcospan, the sarcoglycan complex, and the 
dystroglycan exit the ER unassembled and arrive at the golgi. B, At the golgi 
αDG is O-glycosylated. While still in the golgi the dystroglycans, sarcoglycan 
complex, and sarcospan fully assemble and are transported to the sarcolemma. 
C, Dystrophin, the syntrophins and linkage to the basal lamina through laminin 
likely occurs after proper localization and insertion into the sarcolemma.  
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Figure 1-5 Domain structure of delta sarcoglycan including post-
translational modifications and disease causing mutations. N-glycosylation 
(green) occurs at three putative sites that have been determined through 
sequence analysis. Mutations causing limb-girdle muscular dystrophy 2F (purple) 
and linked to DCM (red) occur throughout the extracellular domain. The cysteine-
rich motif exists at the C-terminus and forms a possible short hairpin via disulfide 
bridges (orange). Phosphorylation (blue) occurs at two sites but has so far only 




Sarcoglycan Family Member Mutations and Associated 
Disease(s) 
Cardiovascular Involvement Skeletal Muscle 
Involvement 
α-sarcoglycan Limb-Girdle Muscular Dystrophy 
2D 
Uncommon Progressive muscle 
wasting and weakening 
β-sarcoglycan Limb-Girdle Muscular Dystrophy 
2E 
Frequent development of 
cardiomyopathy 
Progressive muscle 
wasting and weakening 
from mild to severe 
DMD-like 
γ-sarcoglycan Limb-Girdle Muscular Dystrophy 
2C 
Frequent development of 
cardiomyopathy 
Progressive muscle 
wasting and weakening 
δ-sarcoglycan Limb-Girdle Muscular Dystrophy 
2F, Dilated Cardiomyopathy 
Frequent development of 
cardiomyopathy in individuals with 
LGMD2F, DCM caused by 
dominantly inherited mutations 
Progressive muscle 
wasting and weakening 
form mild to severe 
DMD-like 
ε-sarcoglycan Myoclonus Dystonia n/a n/a 
ζ-sarcoglycan n/a n/a n/a 
Table 1-1 Mutations in the sarcolgycans and corresponding striated muscle 






















Alpha SGCA Q16586.1 - 12.8 8.5 8.5 54.5 8.0 
Beta SGCB Q16585.1 12.8 - 37.5 36.0 8.1 37.3 
Gamma SGCG Q13326.4 8.5 37.5 - 70.8 8.4 74.6 
Delta SGCD Q92629.2 8.5 36.0 70.8 - 1.4 75.9 
Epsilon SGCE O43556.6 54.5 8.1 8.4 1.4 - 2.3 
Zeta SGCZ Q96LD1.1 8.0 37.3 74.6 75.9 2.3 - 
Table 1-2 Sequence alignment of sarcoglycan family members. Percent 
Homology was calculated using EMBOSS Pairwise Sequence Alignment Tool for 
proteins (www.ebi.ac.uk/Tools/psa/emboss_needle/) Alignment reveals three 
groups of homologous sarcolgycans 1) δ, γ, and ζ-sarcoglycan; 2) α and ε-






Dilated cardiomyopathy mutations in delta sarcoglycan exert a dominant 
negative effect on cardiac myocyte mechanical stability 
 
ABSTRACT 
 Delta sarcoglycan is a component of the sarcoglycan subcomplex within 
the dystrophin-glycoprotein complex located at the plasma membrane of muscle 
cells. While recessive mutations in delta sarcoglycan cause limb-girdle muscular 
dystrophy 2F, dominant mutations in delta sarcoglycan have been linked to 
inherited dilated cardiomyopathy (DCM). The purpose of this study was to 
investigate functional cellular defects present in adult cardiac myocytes 
expressing mutant delta sarcoglycans harboring the dominant inherited DCM 
mutations R71T or R97Q.  This study demonstrates that DCM mutant delta 
sarcoglycan can be stably expressed in adult rat cardiac myocytes, traffic 
similarly to WT proteins to the plasma membrane, without perturbing assembly of 
the dystrophin-glycoprotein complex. However, expression of DCM mutant delta 
sarcoglycan in adult rat cardiac myocytes is sufficient to alter cardiac myocyte 
plasma membrane stability in the presence of mechanical strain. Upon cyclical 
cell stretching cardiac myocytes expressing mutant delta sarcoglycan R97Q or 
R71T have increased impermeable dye uptake and undergo contractures at 
greater frequencies than myocytes expressing normal delta sarcoglycan. 
Additionally, the R71T mutation creates an ectopic N-linked glycosylation site 
!
! 36!
that results in aberrant glycosylation of the extracellular domain of delta 
sarcoglycan.  Therefore, appropriate glycosylation of delta sarcoglycan may also 
be necessary for proper delta sarcoglycan function and overall dystrophin-
glycoprotein complex function.  These studies demonstrate that DCM mutations 
in delta sarcoglycan can exert a dominant negative effect on dystrophin-
glycoprotein complex function leading to myocardial mechanical instability that 
may underlie the pathogenesis of delta sarcoglycan associated DCM. 
 
Introduction 
The dystrophin-glycoprotein complex (DGC) is a large complex of 
transmembrane and membrane associated proteins that resides in the lateral 
sarcolemma of cardiac and skeletal muscle cells103, 160. The DGC contributes to 
an important functional linkage between the extracellular matrix (ECM) and 
cytoskeletal proteins in muscle cells. The DGC attaches and interacts with the 
cytoskeleton through the binding of dystrophin to f-actin161.  The central 
transmembrane protein dystroglycan completes the link of dystrophin and the 
DGC to the extracellular matrix, and requires the functional glycosylation of 
alpha-dystroglycan to serve as a high affinity matrix receptor16, 161, 162. The critical 
functional roles of the DGC in muscle are still debated, but may include 
regulation of cell signaling44, 51, muscle force transmission 163-166, and promoting 
plasma membrane stability during muscle contraction68, 111, 143, 144, 167, 168. 
Contained within the DGC is a subcomplex of proteins known as the sarcoglycan 
complex that includes sarcoglycans and sarcospan169-172. Delta sarcoglycan!
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(δSG) is one of six known transmembrane sarcoglycans (α,!β,!γ,!δ,!ε,!ζ) that are 
expressed in a tissue specific manner to form the tetrameric sarcoglycan 
complex 38, 40, 43, 98, 99, 173, 174. Delta, beta and gamma sarcoglycan are highly 
expressed in skeletal and cardiac muscle116 and while alpha-sarcoglycan is the 
prominent fourth member of the sarcoglycan complex in skeletal muscle, cardiac 
muscle expresses both alpha and epsilon-sarcoglycan. Alpha and epsilon 
sarcoglycan proteins are capable of compensating for the loss of each other 
within the cardiac muscle sarcoglycan complex101.  
A critical role of δSG and the sarcoglycan complex in muscle is revealed 
by the fact that recessive mutations in!α,!β,!γ,!and!δ!sarcoglycan have been linked 
to limb girdle muscular dystrophy (LGMD types 2D, 2E, 2C, 2F respectively)175.  
Genetic deletion of any of these four sarcoglycans in mice results in a dystrophic 
muscle phenotype176.   In addition, recessive!δSG mutations are responsible for 
the cardiac and skeletal muscle phenotypes of the cardiomyopathic BIO 14.6 
hamster177.  In addition to progressive skeletal myopathy, patients with 
sarcoglycan associated LGMD have a high prevalence of cardiomyopathy116, 156.  
Recessive mutations in δSG cause reduction or total loss of the sarcoglycan 
complex at the plasma membrane and are thereby thought to disrupt overall 
DGC function. 
In contrast to recessive mutations in!δSG that result in skeletal muscle 
dystrophy, dominantly inherited mutations in δSG have been linked to familial 
dilated cardiomyopathy157 (DCM). The dominantly inherited mutations in δSG do 
not appear to cause skeletal muscle disease and therefore may exert specific 
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effects in cardiac muscle or in the vasculature. Some of the initial studies on 
patients carrying these mutations suggested a possible haploinsufficiency 
mechanism of action.    Mutations in!δSG causing truncation at lysine residue 238 
(ΔK238), in some pathological samples, resulted in decrease in sarcoglycan 
expression at the plasma membrane157. However, one patient identified with this 
mutation showed normal expression patterns of the DGC proteins but still 
developed DCM157.  Transgenic mice expressing the S151A mutation in!δSG that 
is linked to DCM in the heart159 show early lethality, loss of the sarcoglycan 
complex at the plasma membrane in cardiac myocytes, and a sequestration of 
nuclear proteins in cardiac muscle, suggesting a possible dominant negative 
mode of action. However, a study of a large consanguineous family with 
recessive loss of function LGMD2F mutations in the SGCD gene (which encodes!
δSG), revealed that carriers of SGCD mutations that cause LGMD2F, do not 
have evidence of cardiomyopathy arguing against haploinsufficiency as a causal 
mechanism of action for DCM. Furthermore, a subset of the individuals carrying 
the LGMD2F mutation, also carried the S151A polymorphism without DCM or 
LMGD2F, and there was no family history of heart disease153. Despite the 
controversy raised regarding the link between the S151A mutation and DCM, 
independent groups have found additional mutations in!δSG in patients with 
autosomal dominant DCM158 and more recently polymorphisms in delta 
sarcoglycan are a risk factor for HCM178, 179.  Therefore, significant questions 
remain about if and how mutations in δSG cause DCM, and if mutations in!δSG 
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can truly exert a dominant effect on DGC function that directly impacts cardiac 
muscle and may lead to cardiomyopathy in humans.   
 To directly test the hypothesis that DCM associated mutations in!δSG 
exert a dominant effect on DGC function, we expressed wild type δSG and δSG 
containing mutations R97Q or R71T previously linked to DCM153, 157, 158 in adult 
cardiac myocytes to study their direct acute effects on the DGC and function of 
cardiac muscle cells. Adult cardiac myocytes expressing mutant δSG R97Q or 
R71T showed no alterations in the trafficking or localization of the mutant!δSG to 
the plasma membrane. Additionally, expression of either mutant δSG R97Q or 
R71T does not appear to alter expression or assembly of the DGC in rat cardiac 
myocytes. However using a functional assay previously used to study cardiac 
myocytes from mice with recessive muscular dystrophy180, the sarcolemma in 
cardiac myocytes expressing either mutant δSG R71T or R97Q was shown to be 
unstable under conditions of increased mechanical strain resulting in increased 
uptake of membrane impermeable dye and cell contracture.  Finally, cardiac 
myocytes expressing mutant δSG R71T show a unique alteration of N-linked 
glycosylation of δSG, due to creation of an ectopic consensus N-glycosylation 
site by the R71T mutation. Together these support the conclusion that DCM-
linked mutations!δSG can have a dominant negative effect on cardiac myocyte 
function similar to dystrophic cardiomyopathy, and the R71T mutation suggests a 
possible link between post-translational modifications of mutant!δSG and the 





Cardiac Myocyte Isolation: 
200-gram female Sprague Dawley rats were anaesthetized with 20 mg ketamine 
and 4 mg xylazine with 400 units heparin to prevent clotting 20 minutes prior to 
heart removal. The heart was removed and placed on a modified Langendorff 
perfusion apparatus. Perfusion was performed for 5 minutes at a flow rate of 8 
ml/min using Krebs Henselait Buffer (KHB) (118 mmol/L NaCl, 25 mmol/L Hepes, 
1.2 mmol/L KH2PO4, 1.2 mmol/L MgSO4, 1.0 mmol/L CaCl2, 11 mmol/L Glucose). 
Perfusion proceeded for 5 minutes using KHB without Ca2+ at a flow rate of 8 
ml/min. 14895 total units of Collagenase type 2 (Worthington Biochem 
LS004174) was added to the perfusate in 60 ml of perfusate solution. The heart 
was perfused for 20 minutes using recirculated collagenase-KHB (Ca2+ free) 
solution. After 20 minutes of recirculated perfusion the solution the Ca2+ 
concentration was brought up to 1.5 mmol/L using 4 additions at 225 µl of 100 
mmol/L sterile CaCl2 at 30 second intervals. Recirculating perfusion continued for 
an additional 20 minutes. The heart was then removed from the perfusion 
apparatus into a sterile beaker containing 15 ml of Ca2+-collagenase-KHB 
solution. Aorta, and atrium were removed using scissors and ventricular tissue 
was minced into 8 small pieces. Ventricular tissue in sterile beaker was manually 
swirled gently for 5 minutes in a water bath at 37°C. Solution was removed, and 
discarded. 15 ml of new Ca2+-collagenase-KHB solution was added to ventricular 
tissue. Gentle swirling was repeated another 5 minutes and solution was again 
discarded. 15 ml of new Ca2+-collagenase-KHB solution was again added to 
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ventricular tissue. Gentle swirling, solution removal and new solution addition 
was performed once more. Remaining ventricular tissue was passed through 
wide bore sigma-coted (Sigma Aldrich SL2-25) glass pipettes to further liberate 
ventricular myocytes from tissue. Gentle swirling was repeated for a final 5 
minutes-total number of swirling digestions performed was 4. Upon final 
digestion/swirling the solution was passed through a tissue sieve with #10 mesh 
screen (Bellco Glass, Inc.). Collected cells and solution were centrifuged at 18g 
for 3 minutes. Solution was aspirated and isolated cell pellet was resuspended in 
10 ml KHB with 1.0 mmol/L Ca2+ and 2% bovine serum albumin. Ca2+ was 
increased to 1.75 mmol/L by adding 25µl or 100mmol/L CaCl2 3 times at 5 
minute intervals. After final addition of Ca2+ and 5 minute incubation the cell 
suspension was centrifuged at 18g for 3 minutes. Supernatant was aspirated and 
the cell pellet was suspended in 3 ml MEM (Gibco 11575). Cells were counted 
using a hemocytometer and suspended at a final concentration of 100,000 
cells/ml in MEM with 5% FBS. A total of 6 rats were used for membrane 
fluorescence experiments. A total of 6 rats were used for stretch assay 
experiments. A total of 6 rats were used for all western blots. Overall a total of 18 
rats were used for these experiments.  
Cardiac Myocyte Plating: 
Glass cover slips and Bioflex plates (Flex Cell International BF-3001U) were 
coated with 200 ml EHS laminin (Sigma Aldrich L2020) at a concentration of 50!
µg/ml or were plated on 100mm culture dishes (Corning 430167) coated with 1 
ml EHS laminin at a concentration of 50!µg/ml. All plates and dishes coated with 
!
! 42!
laminin were exposed to ultraviolet light for sterilization for 5 minutes and allowed 
to polymerize for 30 minutes prior to myocyte plating. 20,000 total cells in 200!µl 
MEM with 5% FBS were suspended on each cover slip or flex well and allowed 
to adhere for 2 hours. 1,000,000 total cells in 1 ml MEM with 5% FBS was 
suspended on each 100 mm plate and allowed to adhere for 2 hours. Media was 
aspirated from cells adhered to laminin and isolated cardiac myocytes were 
recovered with 3 ml MEM without FBS on Bioflex plates and glass cover slips 
and 10 ml MEM  without FBS on 100 mm plates.  
Cardiac Myocyte Transduction: 
Cardiac myocytes were transduced in MEM (Gibco 11575) for 1 hour. MEM was 
aspirated and replaced with fresh MEM and cells were cultured for 48 hours to 
express delta sarcoglycan. 
Fixed Cardiac Myocyte Immunostaining: 
Rat cardiac myocytes were plated on glass cover slips and coated with 200!µl 
EHS laminin at a concentration of 50 µg/ml and transduced with adenoviral 
vectors. Cardiac myocytes were allowed to express transgenes for 48 hours. 
Media was aspirated and cardiac myocytes were washed with DPBS (GIBCO 
14190). DPBS was aspirated and cardiac myocytes were fixed with 2 ml of 1 
mol/L paraformaldehyde (3%) in DPBS for 10 minutes. Paraformaldehyde was 
aspirated and cardiac myocytes were washed with 5 ml DPBS for 5 minutes 3 
times. The final wash of DPBS was aspirated and the cardiac myocytes were 
blocked for 2 hours with 2 ml block solution (DPBS with 5% BSA and 0.5% 
Triton-X 100). Block solution was aspirated and cardiac myocytes were 
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incubated with primary antibodies using 300 µl/slip of antibodies suspended in 
block solution for 90 minutes in a humidity chamber to prevent block solution 
evaporation. Cardiac myocytes were washed with 5 ml DPBS for 5 minutes 3 
times. The final wash was aspirated and the cardiac myocytes were incubated 
with secondary antibodies suspended in block solution using 300!µl/slip for 1 
hour in a humidity chamber to prevent block solution evaporation. Cardiac 
myocytes were washed with 5 ml DPBS for 5 minutes 3 times. The final wash 
was aspirated and cover slips were mounted on Superfrost Plus microscope 
slides (Fisher Scientific 12-550-15) in aqueous permafluor (Lab Vision TA-030-
FM). For myc-tagged immunofluorescence primary antibody used was A-14 a 
rabbit polyclonal anti-myc (Santa Cruz Bioscience) at a titer of 1:100, secondary 
antibodies used were Cy3 conjugated anti-rabbit IgG (Jackson Immunoresearch) 
at a titer of 1:200, and DAPI (Sigma-Aldrich) diluted 1:10,000 from a 10 mg/mL 
stock solution. For delta sarcoglycan immunofluorescence primary antibody used 
was a goat anti-human delta sarcoglycan (R&D Systems) at a titer of 1:1000, 
secondary antibodies used were Cy3 conjugated anti-goat IgG (Jackson 
Immunoresearch) at a titer of 1:200, and DAPI (Sigma-Aldrich) diluted 1:10,000 
from a 10 mg/mL stock solution. For glycosylated alpha dystroglycan 
immunofluorescence primary antibody used was mouse IIH6 anti-alpha 
dystroglycan (Upstate) at a titer of 1:1000, secondary antibodies used were Cy3 
conjugated anti-mouse IgM (Jackson Immunoresearch) at a titer of 1:200, and 
DAPI (Sigma-Aldrich) diluted 1:10,000 from a 10 mg/mL stock solution. For beta 
dystroglycan immunofluorescence primary antibody used was mouse anti-beta 
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dystroglycan (Vector Labs) at a titer of 1:1000, secondary antibodies used were 
Cy3 conjugated anti-mouse IgG (Jackson Immunoresearch) at a titer of 1:200, 
and DAPI (Sigma-Aldrich) diluted 1:10,000 from a 10 mg/mL stock solution. 
Live Cell Labeling: 
Rat cardiac myocytes were plated on glass cover slips and coated with 200!µl!
EHS laminin at a concentration of 50!µg/ml and transduced with adenoviral 
vectors. Cardiac myocytes were allowed to express transgenes for 48 hours. 
Media was aspirated and cardiac myocytes were incubated with primary antibody 
suspended in MEM (Gibco 11575) for 2 hours at 37°C. Cardiac myocytes were 
washed with 5 ml MEM for 5 minutes 3 times. After final aspiration of media 
cardiac myocytes were fixed with 2 ml of 1 mol/L paraformaldehyde (3%) in 
DPBS for 10 minutes. Paraformaldehyde was aspirated and cardiac myocytes 
were washed with 5 ml DPBS for 5 minutes 3 times. The final wash of DPBS was 
aspirated and the cardiac myocytes were blocked for 2 hours with 2 ml block 
solution (DPBS with 5% BSA and 0.5% Triton-X 100). Block solution was 
aspirated and the cardiac myocytes were incubated with secondary antibodies 
suspended in block solution using 300!µl/slip for 1 hour in a humidity chamber to 
prevent block solution evaporation. Cardiac myocytes were washed with 5 ml 
DPBS for 5 minutes 3 times. The final wash was aspirated and cover slips were 
mounted on Superfrost Plus microscope slides (Fisher Scientific 12-550-15) in 
aqueous permafluor (Lab Vision TA-030-FM). For myc-tagged 
immunofluorescence primary antibody used was A-14 a rabbit polyclonal anti-
myc (Santa Cruz Bioscience) at a titer of 1:100, secondary antibodies used were 
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Cy3 conjugated anti-rabbit IgG (Jackson Immunoresearch) at a titer of 1:200, and 
DAPI (Sigma-Aldrich) diluted 1:10,000 from a 10 mg/mL stock solution. 
Immunofluorescence Microscopy: 
All microscope images were taken using an Olympus BX51 Microscope & DP70 
Digital Camera System. Baseline for exposure of fluorescence images was 
established using isolated cardiac myocytes stained without primary antibodies.  
Membrane Fluorescence Scoring: 
Cardiac myocytes were assessed via random field counts. Five separate 
experiments were performed using five random field counts each at 200X 
magnification. Membrane fluorescence was determined as those rod-shaped 
cells that were also fluorescent above untransduced control cells. 
Cell Stretching Assay: 
Rat cardiac myocytes were plated on Bioflex plates coated with 200!µl EHS 
laminin at a concentration of 50 µg/ml and transduced with adenoviral vectors. 
Cardiac myocytes were allowed to express transgenes for 48 hours. Cardiac 
myoctes were incubated with 50!µg/ml propidium iodide in culture media 
immediately prior to stretch protocol. Cardiac myocytes were stretched with an 
FX4000 Tension System (FlexCell International). Stretch was done using a 
pressure protocol that imparts a 20% length change across the plate at a 
frequency of 1 Hz for 24 hours. After completion of stretch protocol cardiac 
myocytes were undisturbed for 30 minutes. Media and dye solution was 
aspirated and cardiac myocytes were washed twice 5 ml DPBS (GIBCO 14190). 
DPBS was aspirated and cardiac myocytes were fixed with 2 ml of 1 mol/L 
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paraformaldehyde (3%) in DPBS for 10 minutes. Paraformaldehyde was 
aspirated and cardiac myocytes were washed twice with 5 ml DPBS for 5 
minutes. Membranes were cut and mounted on Superfrost Plus microscope 
slides (Fisher Scientific 12-550-15) in aqueous permafluor (Lab Vision TA-030-
FM) for fluorescent microscopy.  
Stretch Assay Scoring: 
Cardiac myocytes were assessed via random field counts. Five separate 
experiments were performed using five random field counts each at 200X 
magnification. Images were taken and a double blind performed. Positive cells 
are those expressing fluorescence in the nucleus.  
Protein Collection: 
Rat cardiac myocytes were plated on 100mm culture dishes (Corning 430167) 
coated with 1 ml EHS laminin at a concentration of 50!µg/ml and transduced with 
adenoviral vectors. Cardiac myocytes were allowed to express transgenes for 48 
hours and were collected with a cell lifter using 500 µl 1% digitonin in DPBS with 
protease inhibitors (benzamidine 0.6 mmol/L, phenylmethylsulfonyl fluoride 0.4 
mmol/L, pepstatin 0.73 µmol/L, Aprotinin 2 KIU/ml, Leupeptin 2.34!µmol/L). 
Cardiac myocytes were vortexed and sonicated for 10 seconds each. Cell debris 
was spun down at 14,000g for 2 minutes and supernatant/cell lysate was 
quantified for western blot and glycosidase treatment.  
Glycosidase treatment: 
30 mg of protein lysate was denatured for either EndoH (New England Biolabs) 
or PNGaseF (New England Biolabs) treatment in the supplied denaturing buffer 
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and incubated for 10 minutes at 100°C in a total reaction volume of 80 µl. Protein 
lysate was then incubated with 2 µl (1000 units) of EndoH with 10!µl of supplied 
buffer G5 in a total volume of 100 µl or protein lysate was incubated with 2!µl 
(1000 units) of PNGaseF with 10!µl of supplied buffer G7 and 10 ml of supplied 
supplement NP-40. Both incubations were performed for 60 minutes at 37°C.  
Western Blot: 
Protein lysates and glycosidase treated proteins were separated using 3-15% 
gradient SDS-PAGE gel and transferred to a PVDF membrane at 100 volts for 3 
hours. Membranes were blocked using 5% non-fat dairy milk in TBS-T (NaCl 150 
mmol/L, Tris pH7.5 50 mmol/L) for 45 minutes. Membranes were incubated with 
primary antibody in 5% non-fat dairy milk in TBS-T overnight. Membranes were 
washed for 10 minutes in TBS-T three times and incubated with secondary 
antibody in 5% non-fat dairy milk in TBS-T for 90 minutes. Membranes were 
washed for 10 minutes in TBS-T three times and incubated in SuperSignal West 
Dura Substrate (Thermo Scientific) for 60 seconds. Visualization of western blots 
was performed using a Fluorochem System (Alpha Innotech). For western blot of 
myc-tagged proteins primary antibody used was A-14 rabbit polyclonal anti-myc 
(Santa Cruz Bioscience) at titer of 1:500 and secondary antibody used was HRP 
conjugated anti-rabbit IgG (Jackson Immunoresearch) at a titer of 1:1000. For 
western blot of beta dystroglycan primary antibody used was A-14 rabbit 
polyclonal anti-myc (Santa Cruz Bioscience) at titer of 1:500 and secondary 
antibody used was HRP conjugated anti-rabbit IgG (Jackson Immunoresearch) at 
a titer of 1:1000. For western blot of beta dystroglycan primary antibody used 
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was mouse anti-beta dystroglycan (Vector Labs) at a titer of 1:500, secondary 
antibodies used was HRP-conjugated anti-mouse IgG (Jackson 
Immunoresearch) at a titer of 1:1000. 
Statistics: 




DCM mutant delta sarcoglycans can be expressed in adult cardiac myocytes at 
similar expression levels to WT delta sarcoglycan.   
Adenoviral vectors containing delta sarcoglycan expression constructs 
were generated using previously described techniques181. The constructed 
adenoviral vectors use the cytomegalovirus (CMV) promoter to drive expression 
of wild type (WT) and mutant human δSG cDNA. A myc tag was engineered on 
the extracellular C-terminus in order to identify the exogenous protein and study 
its cellular trafficking and sarcolemma localization (Figure 2-1A). Adult rat cardiac 
myocytes were isolated and transduced with adenoviral vectors expressing WT 
or mutant δSG. Cardiac myocytes were collected at 24, 48, and 72 hours post-
transduction. The adenoviral expressed!δSG proteins became first detectable at 
approximately 18-24 hours post-transduction and continued to increase until 
expression levels stabilized between 48 and 72 hours post-transduction (Figure 
2-1B). Protein expression after 72 hours did not appear to increase (data not 
shown), indicating a stable level of expression had been achieved. Importantly, 
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under these viral transduction conditions, similar levels of!δSG protein expression 
by western blot were obtained in WT, and R97Q and R71T mutant δSG 
expressing cardiac myocytes (Figure 2-1B).For wild type!δSG, and!δSG mutant 
R97Q or R71T vectors, equivalent titers of virus were required to achieve 
maximal transduction efficiency of nearly 100% of adult cardiac myocytes in vitro 
as detected by immunofluoresence staining using the anti-myc antibody (Figure 
2-1C, 2-1D). These data indicate that R97Q and R71T mutant!δSG can be 
expressed at levels equivalent to WT δSG and the mutants appear to have 
normal protein stability when expressed in adult cardiac myocytes.   
 
Adult rat cardiac myocytes expressing R97Q or R71T mutant!delta sarcoglycan 
do not show DGC disruption or loss of cell viability. 
Genetic disruption of!δSG or other sarcoglycan members in mice results in 
loss of expression of the entire sarcoglycan complex at the sarcolemma in 
muscle cells, and while dystrophin and dystroglycan are still expressed, their 
expression levels are significantly reduced91, 101, indicating null mutations in δSG 
can disrupt DGC assembly in cardiac muscle. In contrast, over-expression of wild 
type!δSG,!δSG mutant R97Q or R71T using adenoviral vectors has no apparent 
effect on DGC assembly and expression (Figure 2-2 & 2-3). The expression of 
beta dystroglycan, an integral membrane bound component of the DGC, is 
unchanged when mutant!δSG R97Q or R71T is expressed in cardiac myocytes 
(Figure 2-2A). Expression of glycosylated αDG, an essential DGC component for 
functional linkage to the extracellular matrix, appears unchanged in cardiac 
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myocytes expressing!δSG mutants R97Q or R71T (Figure 2-3). 
Immunofluorescence staining shows that the expression of α and!β!sarcoglycan 
and its localization are also unchanged (Figure 2-3) in cardiac myocytes 
expressing δSG mutants R97Q or R71T. Furthermore, the expression of δSG 
mutant R97Q, R71T, or wild type!δSG does not appear to directly affect overall 
adult myocyte viability or cell morphology (Figure 2-2B) at least in quiescent 
myocytes after 24-48 hour of expression.   
 
Delta sarcoglycan mutants R97Q and R71T properly localize to the plasma 
membrane  
Expression of the δSG S151A mutation linked to DCM in hearts of 
transgenic mice reveals that δSG mutant S151A protein accumulates in the 
nucleus and does not localize correctly to the plasma membrane159. Whether this 
defect was due to the level of overexpression or whether this represents a 
common mechanism or a property of other!δSG mutations linked to DCM has not 
been studied. To investigate possible trafficking defects associated with the 
R97Q and R71T mutations in isolated adult rat cardiac myocytes, transduced 
myocytes were first analyzed for localization of the WT and mutant protein in 
fixed and permeabilized myocytes to detect the total cellular distribution of the 
expressed proteins. Immunofluorescent staining using an anti-myc antibody on 
isolated cardiac myocytes expressing δSG proteins shows no apparent 
difference in expression or localization of!δSG mutant R97Q or R71T when 
compared to wild type δSG expressing cardiac myocytes (Figure 2-2C) and did 
!
! 51!
not appear to show any accumulation in the nucleus as previously observed for 
the S151A mutation. Although immunofluorescent staining shows no obvious 
differences in expression or localization of mutant!δSG when compared to wild 
type δSG, the data does not directly demonstrate that the WT or mutant proteins 
are properly integrated into the plasma membrane. Delta sarcoglycan is a type-II 
transmembrane protein that, when inserted into to the membrane, presents the 
C-terminus to the extracellular milieu.  We took advantage of the exposure of the 
C-terminus myc epitope tag, to develop a live cell staining protocol in un-
permeablized cardiac myocytes to quantify the insertion of the expressed!δSG 
into the plasma membrane.  Using live cell myc antibody staining, both δSG 
mutant R97Q and R71T proteins can be labeled at the membrane in 
unpermeabilized cells (Figure 2-4A) suggesting they are properly inserted into 
the plasma membrane. To quantify this membrane trafficking, random field 
counts of cardiac myocytes were scored for detectable membrane fluorescence 
in live cell labeling assays, at time points when the protein can be first detected 
at measureable levels. In order to accurately score myocytes, background 
threshold was established using untransduced myocytes for exposure time and 
sensitivity settings. All subsequent images were taken using the same exposure 
time and settings, therefore any myocyte showing fluorescence above 
untransduced control myocytes was scored as positively labeled at the plasma 
membrane. Based on this scoring, in adult cardiac myocytes both!δSG mutant 
R97Q and R71T proteins localize to the plasma membrane with equal efficiency 
to wild type!δSG (Figure 2-4B). One caveat to this assay is that labeling live cells 
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with antibodies may cause internalization of the antibody due to endocytosis. To 
control for this phenomenon cell labeling experiments can be performed at 4° C 
to decrease endocytosis. Unfortunately the length of time needed to accurately 
and robustly label live cardiac myocytes is significantly longer than the time that 
isolated cardiac myocytes can survive at 4° C. To reduce the possible 
endocytosis of the primary antibody during subsequent labeling steps we 
immediatedly fixed the cells after primary antibody incubation.   The subsequent 
secondary antibody labeling uses both fixation and permeabilization and should 
include any myc antibody that may have been internalized during initial 
incubation. Importantly, live cell labeling of cadiac myocytes expressing mutant 
R97Q or R71T is quantitatively and qualitatively similar to wild type expressing 
cardiac myocytes suggesting the trafficking of delta sarcoglycan to the 
membrane was unaffected by the DCM mutations R97Q and R71T. Finally, to 
determine whether the δSG mutant R97Q and R71T proteins were stable at the 
plasma membrane, cardiac myocytes were treated with cycloheximide 24 hours 
after viral transduction and stained for the myc epitope with live cell labeling 
(Figure 2-5). In the presence of cycloheximide, the sarcolemma incorporated 
R97Q and R71T!δSG were retained at the plasma membrane at levels equivalent 
to WT δSG suggesting they are stably incorporated into the sarcolemma 
membrane.   
 
Delta sarcoglycan mutant R71T is aberrantly glycosylated 
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The presence of N-linked glycosylation of!δSG has been demonstrated in 
skeletal muscle116 and in cultured CHO127 and COS-1 cells110. It is unclear what 
role δSG glycosylation plays in δSG protein and overall DGC function in muscle 
cells or whether!δSG is equivalently glycosylated in all muscle cell types. 
Western blots of cardiac myocyte whole cell lysates treated with glycosidases 
targeting N-glycosylation demonstrated that wild type δSG is glycosylated in 
isolated rat ventricular myocytes. Delta sarcoglycan mutant R97Q protein 
appears to have the same glycosylation and expression pattern as wild type!δSG 
but oddly,!δSG mutant R71T protein shows a higher molecular weight band 
suggesting altered post-translational modification (Figure 2-6A). Incubating cell 
lysates with endoglycosidase H (EndoH) or peptide N-glycosidase F (PNGaseF) 
for one hour was sufficient to restore the migration of δSG mutant R71T to the 
same migration pattern of wild type δSG on Western blots (Figure 2-6B), 
indicating that the high molecular weight band in cardiac myocytes expressing!
δSG mutant R71T represents an alternately N-linked glycosylated form of!δSG. 
The alternate glycosylation of R71T δSG does not appear to be cardiac muscle 
cell specific as the upward shift in MW can be observed when R71T is expressed 
in other rat muscle cell types including rat smooth muscle cells (A7R5) and rat 
skeletal muscle myotubes (L6) (Figure 2-7). Interestingly, the occupancy of the 3 
putative N-glycosylation sites on WT δSG appears to be different in smooth 
muscle cells (Figure 2-7) as indicated by a more prominent higher molecular 
weight band in A7R5 cells. However, the R71T mutation still results in an 
additional upward shift in both bands indicating it does not affect the 
!
! 54!
glycosylation on the other N-glycosylation sites in!δSG.  Interestingly, the 
detection of the expressed protein with anti-human δSG antibody, also results in 
a lower molecular weight band that is not observed with the myc antibody, 
suggesting a possible additional proteolytic processing of the C-terminus of δSG 
in cardiac myocytes.  This form of post translation processing does not appear to 
be different between WT and mutant R97Q or R71T!δSG. 
 
Expression of delta sarcoglycan mutant R97Q or R71T in adult cardiac myocytes 
is sufficient to cause mechanical instability of the plasma membrane following 
stretch 
The mechanisms of how loss of function mutations in δSG and the DGC 
cause cardiomyopathy in models of limb-girdle muscular dystrophy and 
Duchenne muscular dystrophy have received considerable attention.  We and 
others have shown that loss of dystrophin expression, cardiac specific loss of 
dystroglycan expression or function, or loss of sarcoglycan expression, is 
sufficient to cause loss of cardiac membrane integrity in vivo using vital dye 
uptake180, 182, 183.  This loss of sarcolemma instability in dystrophic cardiac muscle 
can be demonstrated in isolated cardiac myocytes by subjecting them to 
mechanical stretching in the presence of cell impermeable dyes 180, 183, 184.  Using 
a modified version of these cell stretch assays in the presence of propidium 
iodide to irreversibly label nuclei of cells that lose sarcolemmal integrity, we 
assessed whether expressing δSG mutant R97Q or R71T exerts a dominant 
negative functional effect on the DGC to cause plasma membrane instability 
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following cell stretching. Cardiac myocytes expressing mutant!δSG R97Q or 
R71T exposed to mechanical strain showed a significant increase in 
impermeable dye uptake and increase in cell contracture leading to rounding of 
cells (Figure 2-8B). To quantify this, WT and!δSG mutant R97Q and R71T 
expressing cardiac myocytes were scored in a blinded fashion for cell 
morphology and dye uptake following mechanical stretch. Delta sarcoglycan 
mutant R97Q and R71T expressing cardiac myocytes showed a significant 
decrease in rod-shaped cells, and concomitant increase in round-shaped cells, 
when compared to wild type!δSG expressing myocytes (Figure 2-9). Nearly all of 
the round-shaped cells following stretch were propidium iodide positive indicating 
that sarcolemma rupture likely leads to calcium induced cell contracture. 
Although there was slight reduction in the total number of cells/cm2 after stretch 
in all groups, the decline in cell density was not statistically different than WT 
cells. This suggests that R97Q or R71T mutant expression does not significantly 
alter how tightly the cells are adhered to the laminin substrate, but that 
expression is sufficient to cause a dominant negative effect of sarcolemma 
stability in adult cardiac muscle cells comparable to what has been previously 
observed in dystrophic cardiac cells.   
 
Discussion 
Recessive mutations in δSG that cause limb-girdle muscular dystrophy 
result in loss of δSG at the plasma membrane and disrupt assembly and function 
of the rest of the DGC91, 127. This study investigated the effects of two dominantly 
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inherited mutations in!δSG, R97Q or R71T in adult cardiac myocytes to provide 
evidence for potential mechanisms underlying their linkage to dilated 
cardiomyopathy in humans. These results indicate that δSG mutant R97Q and 
R71T can be stably expressed in cardiac muscle cells at the sarcolemma without 
disrupting DGC assembly, but exert a dominant negative functional effect 
causing sarcolemma instability similar to what has been observed in other 
models of DGC deficiency. This suggests a prominent functional role for 
sarcoglycans in the overall function of the DGC in stabilizing the plasma 
membrane, considerably more than just an accessory protein necessary for 
proper DGC assembly.    
Previous work using transgenic mice, demonstrated that cardiac specific 
over-expression of S151A mutation previously linked to dominantly inherited 
DCM in resulted in a lethal cardiomyopathy157, 159.  In several lines of these mice 
the S151A protein abnormally trafficked to the nucleus where it sequestered 
other sarcoglycans and other nuclear proteins.  However, in one line of mice with 
high level of expression, the S151A trafficking defect was only penetrant in 
around 60% of the cells.  Further studies of these mice have been difficult 
because of the lethality leading to failure of breeding.  The role of S151A in 
causing DCM in humans has been challenged by studies that found the S151A 
mutation in a large consanguineous family with LGMD2F, but the family 
members carrying this mutation did not have cardiomyopathy153.  We chose to 
focus our attention on other δSG mutations associated R97Q and R71T using a 
highly efficient model system of viral mediated gene transfer to adult cardiac 
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myocytes, that we have previously used to study dominant mutations that lead to 
hypertrophic cardiomyopathy and other forms of myopathy181, 185, 186. Our data 
shows human!δSG mutants R97Q or R71T are capable of being expressed at 
levels comparable to WT δSG, traffic completely normally in adult cardiac 
myocytes, and live cell labeling showed they stably insert into the sarcolemma 
similar to WT proteins without dramatically compromising DGC expression or 
assembly.  While we did observe some intracellular localization of the expressed 
δSG, this was not different between WT and mutant proteins indicating that we 
are likely also detecting a portion of the expressed protein in the secretory 
pathway of permeabilized adult cardiac myocytes following acute expression. 
Furthermore, using live-cell labeling, and cycloheximide treatment reveals that 
mutant δSG R97Q and R71T are stable at the plasma membrane. The results 
indicate that the!δSG mutant R97Q and R71T defects do not arise from a 
deficiency in!δSG localization to the plasma membrane and suggests a 
potentially dominant negative function of the protein at the sarcolemma 
underlying its effects to cause DCM.   
Delta sarcoglycan protein has been shown to be glycosylated in muscle in 
vivo and when expressed in vitro116, 127. Although the function of!δSG 
glycosylation in muscle is unclear it has been established that hypoglycosylation 
of dystroglycan within DGC is critical to its function as a laminin receptor and 
results in muscular dystrophy with associated cardiomyopathy15, 16, 82.  
Surprisingly, when we expressed the!δSG mutant R71T we found an additional 
higher molecular weight band upon western blotting with both anti human-δSG 
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and myc antibodies.  Altering amino acid residue 71 from an arginine to a 
threonine creates a new consensus site for a potential N-linked glycosylation site 
relative to the upstream glutamine at amino acid 69. Glycosidase treatment to 
remove N-glycans revealed for the first time that this ectopic glycosylation site in 
the R71T mutant is highly glycosylated in cardiac muscle cells. The removal of N-
glycans by both EndoH and PNGaseF converted all the glycoforms of the WT 
and!δSG mutant R97Q and R71T to a similar migrating low molecular weight 
protein.  Oddly it was expected that treatment with EndoH would also allow us to 
reveal any trafficking defects since sensitivity to that particular glycosidase 
typically indicates a protein is retained in the endoplasmic reticulum. The fact that 
the WT and mutant proteins appear to be EndoH sensitive is noteworthy, but not 
completely without explanation. The sarcoglycan complex has previously been 
found localized to the plasma membrane and is still sensitive to treatment with 
EndoH91. Additionally, an epsilon sarcoglycan mutation causing myoclonus 
dystonia results in an ectopic N-glycosylation site that becomes glycosylated126. 
Epsilon sarcoglycan can localize to the plasma membrane in mouse brain and 
still retains its sensitivity to EndoH treatment187. This abnormal post translational 
processing of R71T does not appear to be unique to cardiac muscle cells, as the 
R71T mutation resulted in an apparent higher molecular weight when expressed 
in skeletal muscle myotubes.   However, the occupancy of the glycosylation sites 
in smooth muscle cells appears to be slightly different than in it is cardiac muscle 
cells suggesting a potential role of glycosylation in modifying sarcoglycan 
function in a tissue specific manner. The model system developed here, could 
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provide a unique opportunity to dissect the role of the individual glycosylation 
sites on sarcoglycans in the function of the DGC in future studies. Overall, the 
abnormal ectopic glycosylation of δSG may contribute to the functional effects of 
the R71T mutation in cardiac muscle cells.  The ectopic glycosylation and the 
location of the R97Q mutation suggest that the C-terminal extracellular domains 
of delta sarcoglycan may directly contribute to overall DGC function as an 
extracellular matrix receptor.  This conclusion is consistent with previous 
observations in humans that truncation of the C-terminus in gamma-sarcoglycan 
can cause limb girdle muscular dystrophy and cardiomyopathy without causing 
loss of sarcoglycan complex expression188 
 Previous studies have shown that loss of!αDG glycosylation or dystrophin 
deficiency causes plasma membrane instability in cardiac myocytes upon 
mechanical strain180, 184 .To test the hypothesis that these dominantly inherited 
δSG mutants R97Q and R71T cause a dominant negative effect on overall DGC 
function, we investigated the effects of mechanical strain upon cardiac myocytes 
expressing!δSG mutants R97Q and R71T. In these experiments the rat cardiac 
myocytes are adhered to the deformable substrate using a laminin matrix.  
Interestingly, untransduced rat cardiac myocytes are overall much less sensitive 
to mechanical stretching than our previous studies in mouse cells and could 
withstand much longer mechanical stretching experiments180.  However, when 
cardiac myocytes expressing!δSG mutant R97Q or R71T are submitted to 
mechanical strain for 24 hours, there is marked increase membrane permeability 
(increased dye uptake) and that likely leads to calcium induced cell contracture 
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(loss of rod-shaped morphology). This does not appear to be a direct effect on 
cell adhesion in the absence of stretch, given that most of the cells expressing 
R97Q or R71T remain attached to the substrate equivalently to WT cells.  These 
rounded up cells do not appear to be cells that have died during the experiment, 
as while most of the rod and round shaped myocytes are quiescent, many of the 
round shape cells show spontaneous beating behavior (not shown).  
Furthermore, some cells die during the cardiac myocyte isolation and exhibit a 
rounded morphology prior to any experiments, but these cells typically do not 
adhere well and are easily washed off the laminin substrate. Overall, these 
results indicate DCM linked!δSG mutations exert a dominant negative functional 
effect in cardiac myocytes, consistent with a dominant negative functional effect 
on the overall function of the DGC that normally protects the cardiac muscle cell 
membrane against mechanical damage. 
The comparable cardiac myocyte phenotypes between mice with 
hypoglycosylation of αDG and rat cardiac myocytes expressing dominant 
negative δSG mutations raises some important new questions about how 
sarcoglycans may function within the DGC. While, previous studies have 
suggested sarcoglycans may contribute to the interactions of!αDG with the DGC, 
we did not observe any changes in dystroglycan expression, cleavage of βDG or 
the amount of glycosylated αDG detected on the cells surface with the IIH6 
antibody.  Of course it is possible that more subtle protein-protein interactions 
amongst components of the DGC are altered when mutant sarcoglycans are 
expressed. However, overall our studies suggest a possible new hypothesis that 
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the extracellular domains of sarcoglycans contribute directly to the interaction of 
the cell with matrix either within the DGC or perhaps even in a DGC independent 
fashion.  Recent findings that loss of sarcospan, a component of the 
sarcoglycan-sarcospan complex appears to have DGC dependent and DGC 
independent effects on sarcolemma stability in skeletal muscle189, supports the 
idea that sarcoglycans may function more than just as an accessory protein in 
the DGC, but actually play an important prominent direct role in maintaining 
sarcolemma stability in striated muscle.  
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Figure 2-1. Adenoviral vectors driving expression of delta sarcoglycan in 
cardiac myocytes are highly efficient and comparable across all groups. A,!
δSG adenoviral vector design. B, Time course of!δSG expression using 
adenoviral vectors in isolated cardiac myocytes. DCM mutant and wild type!δSG 
protein expression is detectable as early as 24 hours and increases in 
expression over time. DCM mutants and wild type protein expression peaks after 
48 hours post-transduction and stabilizes thereafter. C, Transduction efficiency of 
DCM mutant and wild type adenoviral vectors. Efficiency of transduction 
approaches 100 percent for cardiac myocytes and is similar in δSG mutant and 
wild type!δSG expressing myocytes. Values are normalized as a percentage of 





Figure 2-2. Mutant δSG espression does not affect cardiac myocyte viability 
or cell morphology and does not alter!βDG localization or organization. A, 
Immunostaining for!βDG. Expressing!δSG mutation R97Q or R71T does not alter 
expression or localization of membrane bound DGC component!βDG. The red 
channel is beta dystroglycan (anti-βDG), and the blue channel is DAPI stained 
nuclei. Scale bars are equal to 50 µm. B, Assessment of cardiac myocyte cell 
morphology. Expressing δSG using adenoviral vectors does not decrease overall 
cardiac myocyte viability and does not alter rod morphology. Values are 
normalized as a percentage of the total population of cells and values are 
represented as mean  + S.E. C, Immunostaining for!δSG in cardiac myocytes 
following fixation and permeabilization. The red channel is myc-tagged!δSG (anti-
myc) and the blue channel is DAPI stained nuclei. There is no apparent 
difference in expression levels or localization in wild type or δSG mutant R97Q or 
R71T expressing cardiac myocytes. Scale bars are equal to 50 µm.  
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Figure 2-3. Expressing delta sarcoglycan using adenoviral vectors does not 
alter DGC localization or organization. Immunostaining for δSG, αSG, βSG,!
βDG, and glycosylated αDG (IIH6) reveals expression levels for DGC 
components is unaffected by expression of mutant δSG protein R97Q or R71T 
compared to wild type δSG. DGC localization appears unaffected as well. Scale 





Figure 2-4. DCM mutant!δSG R97Q and R71T localize and insert normally 
into the plasma membrane. A, Live-cell labeling of!δSG. The red channel 
represents!δSG (anti-myc) and the blue channel is DAPI. Live-cell labeling 
identifies only!δSG inserted into the plasma membrane. Red levels have been 
adjusted evenly across all panels to allow visualization of staining above 
background. Expression levels and membrane labeling are similar in wild type as 
well as δSG mutant R97Q and R71T expressing cardiac myocytes. Staining with 
anti-myc antibody shows labeling only in cells that have been transduced with 
myc-tagged wild type δSG or!δSG mutant R97Q or R71T. Scale bars are equal to 
50!µm. B, Quantifying cardiac myocytes labeled with δSG at the plasma 
membrane. Delta sarcoglycan mutant R97Q and R71T have no significant 
difference in cardiac myocytes labeled at the plasma membrane when compared 
to wild type!δSG expressing cardiac myocytes. Values are normalized as a 




Figure 2-5. Mutant!δSG protein R97Q and R71T are stable at the plasma 
membrane. Live cell staining and treatment with cycloheximide reveals!δSG 
protein turnover at the plasma membrane is similar in cardiac myocytes 
expressing mutant δSG R97Q and R71T compared to wild type!δSG. All panels 
have been adjusted equally to better visualize membrane staining. Scale bars 
are equal to 200 µm. 
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Figure 2-6. DCM mutant!δSG R71T expressed in cardiac myocytes 
undergoes alternative glycosylation. A, Western blot analysis of whole cell 
lysates taken from rat cardiac myocytes. Using an antibody directed against 
human δSG reveals additional bands in cardiac myocytes expressing DCM 
mutant δSG R71T. Probes using antibodies directed against delta sarcoglycan 
produce multiple bands in all cell types but a molecular weight shift only in 
cardiac myocytes expressing!δSG mutant R71T B, Western blot analysis of 
whole cell lysates subjected to glycosidase treatment using anti-myc antibody. 
Treating with EndoH and PNGaseF shows additional bands present in cardiac 
myocytes expressing DCM mutant δSG R71T are alternatively glycosylated 




Figure 2-7. Alternative glycosylation of mutant δSG R71T occurs in other 
cell culture models of striated muscle and A7R5 cells have increased 
overall glycosylation. Western blot analysis of whole cell lysates (anti-myc) 
taken from rat cardiac myocytes, smooth muscle A7R5 cells, and skeletal muscle 
L6 myotubes. Blotting reveals differential glycosylation of!δSG in rat cardiac 
myocytes is recapitulated in skeletal muscle L6 myotubes. Additionally, A7R5 
cells show multiple bands in both mutant and WT expressing cells and an 
accompanying molecular weight shift when!δSG mutant R71T is expressed. 




Figure 2-8. Mechanical stretch increases cell contracture and cell 
impermeable dye uptake in cardiac myocytes. Cells submitted to stretch are 
more susceptible to dye uptake and cell rounding than cells that are not 
mechanically strained. A, Diagram demonstrating experimental design for 
subjecting isolated cardiac myocytes to mechanical strain. B, Non-stretched and 
stretched cardiac myocytes. The fields shown are an example of the stretch 
effect using cardiac myocytes expressing δSG mutant R71T. Overall 
fluorescence is lower and there are fewer positively labeled cells in non-stretched 
fields. Stretching myocytes increases uptake of membrane impermeable 
propidium iodide and causes an increases in total number of round-shaped cells. 




Figure 2-9. Cardiac myocytes expressing DCM mutants!δSG R97Q and 
R71T are more susceptible to sarcolemmal damage due to mechanical 
strain compared to cardiac myocytes expressing wild type δSG. Scoring 
cardiac myocytes following a 24-hour protocol of mechanical strain. The top 
graphs are normalized as a percentage of the cell population within each 
experiment. The top-left graph shows the overall percentage of cells retaining the 
normal rod-shaped morphology. The top-middle graph shows the overall 
percentage of cells that are abnormally round-shaped. The top-right graph shows 
the number of positively labeled round-shaped cardiac myocytes. Cardiac 
myocytes expressing!δSG mutant R97Q or R71T have a statistically significant 
decrease in normal rod-shaped cells and a significant increase in abnormal 
round-shaped cells. Additionally, cardiac myocytes expressing!δSG mutant R97Q 
or R71T have a statistically significant increase in the number of positively 
labeled round cells. Positive labeled cells are those cells defined as having 
fluorescence above background. The bottom graphs show the change in number 
of cardiac myocytes counted before and after mechanical strain. The bottom-left 
graph shows the change in total number of cardiac myocytes. The bottom-right 
graph shows the change in normal rod-shaped cardiac myocytes. Cardiac 
myocyte populations expressing!δSG mutant R97Q or R71T do not show a 
statistically significant difference in overall total cells when exposed to 
mechanical strain. Cardiac myocyte populations expressing!δSG mutant R97Q 
and R71T do show a statistically significant decrease in rod-shaped cells. Delta 
was expressed by subtracting the number of cells counted without stretch from 






Glycosylation of Delta Sarcoglycan’s Extracellular Domain is Necessary to 




 Delta sarcoglycan is an integral component of the dystrophin-glycoprotein 
complex and necessary for sarcoglycan complex assembly and function. 
Mutations in the extracellular domain of delta sarcoglycan are responsible for 
both limb-girdle muscular dystrophy 2F and are linked to development of dilated 
cardiomyopathy. The extracellular domain of delta sarcoglycan also undergoes a 
number of post-translational modifications including three putative sites for N-
linked glycosylation at threonine residues 60 and 108, as well as serine residue 
284. The purpose of this study was to investigate the role these residues play in 
delta sarcoglycan function. Using isolated rat cardiac myocytes as a model these 
data demonstrate that N-linked glycosylation of delta sarcoglycan only occurs at 
residues 108 and 284. Additionally, residue 108 is N-glycosylated on all delta 
sarcoglycan proteins whereas residue 284 appears to be occupied on only one 
quarter of all delta sarcoglycan proteins. The loss of glycosylation at residue 108 
or 284 also does not affect delta sarcoglycan localization to the plasma 
membrane. Furthermore loss of glycosylation at residue 108 causes decreased 
myocyte adhesion to laminin following mechanical strain. Together these data 
suggest that fully gycosylated delta sarcoglycan may play a supporting role in 
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stabilizing the attachment of the dystrophin-glycoprotein complex to laminin 
during mechanical events. 
 
Introduction 
 Delta sarcoglycan (δSG) is member of the tetrameric sarcoglycan complex 
expressed highly at the lateral sarcolemma in striated muscle transcoded by the 
SGCD gene in humans on chromosome 5. The δSG protein was first identified as 
a 35-kD glycoprotein associated with the dystrophin-glycoprotein complex (DGC) 
almost 20 years ago41. That same year it was determined that an autosomal 
recessive mutation in the SGCD gene was responsible for limb-girdle muscular 
dystrophy type 2F (LGMD2F)156. Not long after the initial discovery of δSG it was 
identified as the gene product deficient in the BIO 14.6 Syrian hamster177, a 
widely used animal model of dilated cardiomyopathy (DCM). Later candidate 
gene studies revealed that dominantly inherited mutations in the SGCD gene 
were linked to familial DCM157. Since the initial discovery of δSG many more 
mutations have been identified linked to both LGMD2F112, 153-155 and DCM158. The 
presence of multiple mutations that cause varying severe muscle diseases 
suggests that the δSG protein plays an integral role in muscle function. Despite 
this, δSG protein function remains largely a mystery. It is hypothesized that the 
sarcoglycans stabilize the DGC at the sarcolemma97, 128, 134, 142, 190, 191, but how 
the sarcoglycan complex performs this action is not completely clear.  
 Mutations in δSG that cause LGMD2F also destabilize the sarcoglycan 
complex94, 112, 192 making it difficult to establish a possible functional role for the 
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singular protein δSG beyond the overall function of the sarcoglycan complex. 
This is likely due to δSG being an obligate half of the δ/β sarcoglycan complex 
core. The disruption of the δ/β sarcoglycan core causes complete sarcoglycan 
complex loss and a subsequent dystrophic phenotype110, 128, 129. The 
δ/β sarcoglycan core is not only the first necessary step in sarcoglycan complex 
assembly but also appears to interact with dystrophin through both δ and βSG 
cytosolic tails110.   
 Previous work in our lab suggests that DCM linked δSG mutations R97Q 
and R71T act as dominant negative proteins when integrated into the DGC and 
sarcolemma (Chapter 2). These two δSG mutants functionally disrupt plasma 
membrane stability during mechanical strain. The dominant negative action of 
these two mutants suggests that δSG has a functional role that can be disrupted 
without also disturbing the sarcoglycan complex. Additionally, the mutation at 
residue 71 from an arginine to a threonine creates an ectopic consensus site for 
N-linked glycosylation. Despite the addition of this ectopic glycan the mutant δSG 
localizes to the plasma membrane and integrates with normal efficiency. 
Previous data has suggested that residues 57-92 in δSG are necessary for 
proper association with βSG110. The mutation of residue 71 and ectopic 
glycosylation would normally suggest that this mutation has a role in destabilizing 
the δSG and βSG interaction. However, expression of δSG mutant R71T does 
not have an apparent change in βSG expression or localization to the plasma 
membrane (Chapter 2). Expressing δSG mutant R71T and retaining an intact 
sarcoglycan complex naturally leads to questions about the role that glycan 
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residues play in δSG protein function and how mutations in the extracellular 
domain of δSG alter this function.  
 The extracellular domain of δSG comprises over 80 percent of the amino 
acids that make up the δSG protein. Additionally, due to glycosylation it likely 
also makes up the bulk of δSG’s mass. Sequence analysis identifies three 
consensus sites for N-linked glycosylation at residues 60-62 (NFT), 108-110 
(NVT), and 284-286 (NTS). These putative sites have not been experimentally 
verified, and more importantly the role of N-linked glycosylation in δSG protein 
function is still unknown. Prevailing thought concerning sarcoglycan glycosyl 
residues is that they are responsible and necessary for proper protein folding and 
processing through the secretory pathway193-196. However, three pieces of 
evidence exist that suggest N-linked glycosylation of sarcoglycans may play a 
more active role in δSG and sarcoglycan complex function. 1) Ectopic 
glycosylation at residue 71 in mutant δSG R71T is processed and localizes 
normally to the sarcolemma in cardiac myocytes (Chapter 2). 2) Glycosylation of 
DGC protein αDG is responsible for binding to the extracellular matrix through 
laminin16, 81-87. 3) Gain-of-glycosylation mutations in epsilon sarcoglycan (εSG) 
can cause myoclonus dystonia126 
 This study investigated the functional role δSG glycan residues play in 
sarcolemma stabilization and extracellular matrix interactions. Adenoviral vectors 
were designed mutating the asparagine to glutamine residues in each of the 
three putative glycosylation sites in δSG. Isolated rat cardiac myocytes 
expressing glycan mutant demonstrate that glycosylation does not occur on 
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asparagine residue 60. Asparagine residue 108, is glycosylated on all δSG 
proteins in cardiac myocytes. Finally, asparagine residue 284 is glycosylated on 
approximately 23 percent of δSG proteins in cardiac myocytes. Additionally, 
ablation of glycan residues at either 108 or 284 does not inhibit δSG protein 
localization to the plasma membrane. Using a functional stretch assay reveals 
that cardiac myocytes expressing glycan mutant N108Q have decreased cell 
adhesion to laminin after mechanical strain. These findings demonstrate that 
glycan residues on δSG are not necessary for protein processing through the 
secretory pathway. Additionally, the data presented here suggests that δSG 




Recombinant Adenovirus Generation: 
Human delta sarcoglycan full-length cDNA was obtained from Open Biosystems 
(MHS1011-7509692) Point mutations creating glycosylation deficient δSG were 
engineered using a QuickChange II site directed mutagenesis kit (Agilent 
200523).  Adenovirus was generated as previously described (Chapter 2). 
Cardiac Myocyte Isolation: 
Anaesthetization (20mg ketamine/4mg xylazine, 400 units heparin) was 
administered via intraperitoneal injection on 200 gram Sprague Dawley female 
rats (Charles River Labs). 20 minutes after anaesthetization rats received 
bilateral thoracic incision and the heart was removed and placed in ice-cold 
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Krebs Henselait Buffer (KHB) (118 mmol/L NaCl, 25 mmol/L Hepes, 1.2 mmol/L 
KH2PO4, 1.2 mmol/L MgSO4, 1.0 mmol/L CaCl2, 11 mmol/L Glucose). Excess 
lung, pulmonary vessels, thymus, and fat were removed prior to attaching to a 
sterile canula and transferring to a modified Langendorff perfusion apparatus. 
Retrograde perfusion was performed through the aorta using 37° KHB for 5 
minutes at approximate 10 ml/min. Temperature was maintained by recirculating 
water bath in an outer chamber. Perfusion is changed to KHB without Ca2+ for 
another 5 minutes at a flow rate of approximately 10 ml/min. Type 2 Collagenase 
(Worthington Biochem LS004174) was added to perfusate at a concentration of 
230 u/ml in a total of 80 ml solution. Perfusion proceeded for 25 minutes with 
recirculation of Ca2+-free KHB solution with collagenase. Ca2+ concentration is 
increased to 1.5 mmol/L using 225 µl of 100 mmol/L sterile CaCl2 added 4 times 
at 30-second intervals. Perfusion and recirculation continued for an additional 25 
minutes. After perfusion the heart is removed from the Langendorff into 20 ml of  
collagenase-Ca2+-KHB solution in a sterile beaker. Ventricular tissue is removed 
and minced into 8-12 small pieces. Ventricular tissue underwent gentle manual 
swirling for 5 minutes at 37°C in a water bath. Solution was removed and 
discarded. 20 ml of new collagenase-Ca2+-KHB solution was added and swirling 
was repeated for an additional 5 minutes. Solution was removed and discarded. 
20 ml of new collagenase-Ca2+-KHB solution was added and ventricular tissue 
was passed through wide-bore pipettes coated with sigma-cote (Sigma Aldrich 
SL2-25). Swirling was repeated again for an additional 5 minutes. Solution was 
removed and discarded. 20 ml of new collagenase-Ca2+-KHB solution was added 
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and ventricular tissue was passed through wide-bore pipettes coated with sigma-
cote (Sigma Aldrich SL2-25). Swirling was repeated again for an additional 5 
minutes bringing the total number of incubations to 4. After the final swirling and 
incubation remaining tissue was passed through a 60-mesh tissue screen. 
Collected myocytes were centrifuged at 300 rpm for 3 minutes. Collagenase-
Ca2+-KHB solution was aspirated and pelleted cardiac myocytes were 
resuspended in 10 ml stop solution (2% bovine serum albumin in KHB). Calcium 
was increased to 1.75 mmol/L by adding 5, 10, 15, 20, and 25 µl 100 mmol/L 
CaCl2 at 5-minute intervals. Cardiac myocytes were centrifuged at 300 rpm for 3 
minutes. Stop solution was aspirated and pelleted cardiac myocytes were 
resuspended in 5 ml minimum essential media (MEM) (Gibco 11575). Cells were 
totaled and counted using a hemocytometer and suspended at a final 
concentration of 100,000 cells/ml in MEM with 5% FBS. A total of 4 rats were 
used for stretch assay experiments. A total of 4 rats were used for membrane 
fluorescence and live-cell staining experiments. A total of 3 rats were used for 
western blots. Overall a total of 11 rats were used for experiments in this cohort.  
Cardiac Myocyte Plating: 
Flexcell plates were coated with 300 µl EHS laminin (Sigma Aldrich L2020) at a 
concentration of 50 µg/ml. Glass cover slips were coated with 100 µl EHS laminin 
at a concentration of 50 µg/ml. 100mm culture dishes (Corning 430167) were 
coated with 1 ml EHS laminin at a concentration of 50 µg/ml. All plates and 
coverslips covered with laminin were sterilized prior to plating myocytes using 
ultraviolet light for 5 minutes and allowed to polymerize at least 30 minutes prior 
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to plating. 30,000 cardiac myocytes were suspended on each bioflex plate and 
allowed to adhere for 2 hours. 10,000 cardiac myocytes were suspended on 
each glass cover slip and allowed to adhere for 2 hours. 1,000,000 cardiac 
myocytes were suspended on each 100 mm plate and allowed to adhere for 2 
hours. Following the 2-hour incubation media was aspirated from cardiac 
myocytes adhered to laminin and replated in MEM without FBS.  
Cardiac Myocyte Transduction: 
Cardiac myocytes were transduced in MEM for at least 1 hour. MEM was 
aspirated and replaced with fresh MEM and cardiac myocytes were allowed to 
express transduced proteins for 48 hours. !
Fixed Cardiac Myocyte Immunostaining: 
After being allowed to express transduced proteins media was aspirated from 
cardiac myocytes and replaced with Dulbecco’s phosphate buffered saline 
(DPBS) (Gibco 14190). DPBS was aspirated and cardiac myocytes were fixed 
with 500 µl of 1 mol/L paraformaldehyde in phospate buffered saline (PBS) for 15 
minutes. Paraformaldehyde was aspirated and fixed cardiac myocytes were 
washed with 500 µl DPBS for 5 minutes a total of 3 times. Cardiac myocytes 
were blocked for 2 hours with 500 µl block solution (DPBS with 5% BSA and 
0.5% triton-X 100) to permeabilize myocytes. Block solution was aspirated and 
cardiac myocytes were incubated in primary antibody using 100 µl/slip antibody 
suspended in block solution for 90 minutes in a humidity chamber. Primary 
antibody was aspirated and cardiac myocytes were washed with 500 µl DPBS for 
5 minutes a total of 3 times. DPBS was aspirated and cardiac myocytes were 
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incubated with secondary antibody using 100 µl/slip using antibody suspended in 
block solution for 1 hour in a humidity chamber. Secondary antibody was 
aspirated and cardiac myocytes were washed using 500 µl DPBS for 5 minutes a 
total of 3 times. DPBS was aspirated and cover slips were mounted in aqueous 
permafluor (Lab Vision TA-030-FM) on Superfrost Plus microscope slides (Fisher 
Scientific 12-550-15). For labeling myc tags primary antibody used was 9B11 
mouse monoclonal anti-myc (Cell Signaling 2276S) at a titer of 1:50, secondary 
antibodies used were Cy3 conjugated anti-mouse IgG (Jackson 
Immunoresearch) at a titer of 1:500 and DAPI (Sigma-Aldrich) diluted 1:10,000 
from a 10 mg/ml stock.  
Live Cell Labeling: 
After being allowed to express transduced proteins media was aspirated from 
cardiac myocytes and replaced with primary antibody in 100 µl MEM (Gibco 
11575) at 37°C for 2 hours. Media and antibody were aspirated and cardiac 
myocytes were washed with 500 µl MEM for 5 minutes a total of 3 times. Cardiac 
myocytes were washed once with 500 µl DPBS (Gibco 14190) and then fixed in 
500 µl 1 mol/L paraformaldehyde for 15 minutes. Paraformaldehyde was 
aspirated cardiac myocytes washed with 500 µl DBS for 5 minutes a total of 3 
times. DPBS was aspirated and myocytes were blocked using 500 µl block 
solution (5% BSA and 0.5% triton-X 100 in DPBS) for a total of 2 hours. Block 
solution was aspirated and replaced with 100 µl secondary antibody suspended 
in block solution for 1 hour in a humidity chamber. Secondary antibody solution 
was aspirated and cardiac myocytes were washed with 500 µl DPBS for 5 
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minutes a total of 3 times. DPBS was aspirated and cover slips were mounted in 
aqueous permafluor (Lab Vision TA-030-FM) on Superfrost Plus microscope 
slides (Fisher Scientific 12-550-15). For labeling myc tags primary antibody used 
was 9B11 mouse monoclonal anti-myc (Cell Signaling 2276S) at a titer of 1:50, 
secondary antibodies used were Cy3 conjugated anti-mouse IgG (Jackson 
Immunoresearch) at a titer of 1:500 and DAPI (Sigma-Aldrich) diluted 1:10,000 
from a 10 mg/ml stock.  
Immunofluorescence Microscopy: 
Images were taken using a Leica SP8 confocal microscope with direct detection. 
Fluorescence baseline was established using myocytes stained without primary 
antibody.  
Membrane Fluorescence Scoring: 
Membrane fluorescence was scored using random field counts. Four 
experiments were performed generating five random field counts for each group 
at 200X magnification. Membrane fluorescence was determined as those rod-
shaped cells that were fluorescent above untransduced control cell threshold. For 
evaluating membrane localization, pixel density was evaluated selecting regions 
of interest using Leica LAS-AF-Lite software. Regions evaluated were total cell 
fluorescence, peripheral fluorescence, intercalated disc fluorescence, and lateral 
membrane fluorescence. Pixel density was used to normalize for variance in the 
size of areas selected. 4 random myocytes from each sample group were used 
to score regions of interests 
Cell Stretch Assay: 
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Isolated myocytes were incubated with 2 µg/ml 7-aminoactinomycin D (7-AAD) 
(Molecular Probes A1310) in MEM (Gibco 11575) immediately prior to 
mechanical stretch. Myocytes were stretched on Bioflex plates via an FX4000 
Tension System (FlexCell International). Stretch was performed using a strain 
protocol imparting 20% length change across the membrane at 1 Hz for 24 
continuous hours. After mechanical strain myocytes were incubated for 30 
minutes undisturbed. Media was aspirated and cardiac myocytes were washed 
with DPBS (Gibco 14190) twice for 5 minutes each. DPBS was aspirated and 
myocytes were fixed using 1 mol/L paraformaldehyde in DPBS for 15 minutes. 
Paraformaldehyde was aspirated and myocytes were washed with DPBS for 5 
minutes 2 total times. Myocytes and membranes were mounted in aqueous 
permafluor (Lab Vision TA-030-FM) on SuperFrost Plus microscope slides 
(Fisher Scientific 12-550-15) for fluorescent microscopy.  
Cell Stretch Assay Scoring: 
Myocytes were counted via random fields. In total 3 separate rat isolations were 
performed. Each experiment generated 15 fields per sample group. Of the 15 
fields generated for each group 5 fields were assessed at random. Images were 
taken and myocyte morphology was scored for all cells in a field. Positive-labeled 
cells were evaluated as having staining in the nucleus above background.  
Protein Collection: 
After being allowed to express transduced proteins media was aspirated from 
cardiac myocytes and collected using a cell lifter in 0.5% SDS in DPBS with 
protease inhibitors (leupeptin 2.34 µmol/L, aprotinin 2 KIU/ml pepstatin 0.73 
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µmol/L, phenymethylsulfonyl fluoride 0.4 mmol/L, benzamidine 0.6 mmol/L). 
Lysate and collected myocytes were vortexed, sonicated, and centrifuged at 
14,000g for 2 minutes to pellet cell debris and supernatant was stored at -80°C 
for future use.  
Western Blots: 
All samples were run on a 3-15% SDS-PAGE gradient gel and wet-transferred to 
PVDF membranes at 100 volts for 3 hours. Membranes were blocked with 5% 
non-fat dairy milk in TBS-T (NaCl 150 mmol/L, Tris pH 007.5 50 mmol/L) for 1 
hour. Following block, membranes were incubated using primary antibody in 5% 
non-fat dairy milk in TBS-T overnight. Membranes were washed using TBS-T for 
10 minutes 3 total times. Membranes were incubated using secondary antibody 
in 5% non-fat dairy milk in TBS-T for 2 hours. Membranes were washed using 
TBS-T for 10 minutes 3 total times and incubated in SuperSignal West Dura 
Substrate (Thermo Scientific) for 1 minute. Membranes were visualized on a 
Fluorochem System (Alpha Innotech). For labeling myc tags primary antibody 
used was 9B11 mouse monoclonal anti-myc (Cell Signaling 2276S) at a titer of 
1:500, secondary antibodies used were HRP-conjugated anti-mouse IgG 
(Jackson Immunoresearch) at a titer of 1:1000. For labeling beta-dystroglycan 
primary antibody used was a mouse monoclonal anti-βDG (AbCam) at a titer of 
1:500, secondary antibodies used were HRP-conjugated anti-mouse IgG 
(Jackson Immunoresearch) at a titer of 1:1000. For labeling beta-sarcoglycan 
primary antibody used was a mouse monoclonal anti-βSG (AbCam) at a titer of 
1:500, secondary antibodies used were HRP-conjugated anti-mouse IgG 
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(Jackson Immunoresearch) at a titer of 1:1000. For labeling alpha-sarcoglycan 
primary antibody used was a mouse monoclonal anti-αSG (University of Iowa 
Developmental Studies Hybridoma Bank IVD (1)A9) at a titer of 1:500, secondary 
antibodies used were HRP-conjugated anti-mouse IgG (Jackson 
Immunoresearch) at a titer of 1:1000. 
Statistics: 




Recombinant Adenoviruses Driving Expression of Glycosylation Deficient Delta 
Sarcoglycan is Highly Efficient 
 Glycosylation deficient delta sarcoglycan adenovirus was engineered 
using previously described techniques181. Vectors used in adenovirus use the 
cytomegalovirus (CMV) promoter to drive expression. Delta sarcoglycan was 
engineered with a C-terminus myc tag and glycosylation consensus sites were 
mutated altering the asparagine residues into glutamine residues (Figure 3-1A) 
using a quick-change site directed mutagenesis kit (Agilent). Rat cardiac 
myocytes were isolated and transduced at varying titers to determine optimal 
transduction efficiency (data not shown). Cardiac myocytes were also isolated, 
transduced and collected at 24, 48, and 72 hours post-transduction to determine 
optimal time for expression (data not shown). In cardiac myocytes expressing 
wild type δSG two distinct bands are present – the lower highly expressed band 
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and an upper band of relatively low expression. In cardiac myocytes expressing 
N60Q mutant δSG there appears to be no change in expression compared to 
wild type δSG indicating that N-linked glycosylation does not occur at the 
consensus sequence from residues 60-62 (Figure 3-1B). In cardiac myocytes 
expressing N108Q mutant δSG both bands are present but shifted downward 
indicating these bands run at a lower molecular weight than wild type δSG. In 
cardiac myocytes expressing N284Q mutant δSG the bottom band is still present 
but the upper band is lost entirely (Figure 3-1B). The one band remaining in 
lysates from N284Q expressing cardiac myocytes runs at an apparently similar 
level to the lower band of wild type delta sarcoglycan expressing cardiac 
myocytes. This suggests that the reduction to one band in the mutant N284Q 
expressing cardiac myocytes is due to ablation of glycosylation at residue 284 
and is not due to some form of proteolytic cleavage. Additionally, the downward 
shift of both bands in cardiac myocytes expressing mutant N108Q appears to 
have a magnitude of around 5-6 kD which is similar to the molecular weight shifts 
observed in other model systems ablating specific sites of N-linked glycans197, 
198, given there may be differences in complexity and charge of the N-linked 
glycans. The upper band in wild type expressing cardiac myocytes representing 
δSG that has been glycosylated on both residue 108 and residue 284 is 
approximately 23 percent of the total δSG protein indicating that glycosylation on 
residue 284 is significantly less efficient than residue 108 (Figure 3-1C). When 
site 108 is mutated causing loss of N-linked glycosylation at this residue the 
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upper band representing δSG glycosylated at residue 284 comprises almost half 
of all δSG proteins.  
Adult Rat Cardiac Myocytes Expressing Glycosylation Deficient Delta 
Sarcoglycan has no Adverse Effects on DGC Expression or Cell Viability 
 Previous studies have demonstrated that δSG is an integral component in 
sarcoglycan complex assembly. The sarcoglycans are necessarily expressed in 
a 1:1:1:1 ratio during assembly116, 127 and the first step in sarcoglycan assembly 
is the association of δSG with βSG110, 128, 129. Destabilization of the sarcoglycan 
complex via loss of δSG N-glycans could disrupt assembly of the sarcoglycan 
complex or dystroglycans at the plasma membrane and could alter DGC 
component stoichiometry. Scoring cardiac myocytes expressing glycan mutant 
δSG shows that loss of glycosylation at residue 108 or 284 has no apparent 
change in cell morphology indicating that overall cell viability is not affected by 
expression of δSG glycan mutants (Figure 3-2A). Additionally, expression of δSG 
glycan mutant N108Q or N284Q in cardiac myocytes does not affect apparent 
expression levels of the dystroglycans or sarcoglycan complex (Figure 3-2B). 
 
Glycosyl Residues on Delta Sarcoglycan are not Necessary for Sarcoglycan 
Complex Assembly or Localization to the Sarcolemma 
 It has been suggested that many of the mutations in δSG that cause loss 
of the sarcoglycan complex may be due to trafficking defects that could be 
rescued using pharmaceutical chaperones through the secretory pathway or 
inhibition of endoplasmic-reticulum-associated protein degradation193-196. DCM-
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linked δSG mutant S151A in mice have a trafficking defect causing foci and 
sequestration of the sarcoglycan complex in the nucleus of cardiac myocytes159 
suggesting that pathogenesis from some mutations in δSG may be caused by 
mislocalization away from the plasma membrane. Whether N-linked glycosylation 
is necessary for δSG processing through the secretory pathway and localization 
to the sarcolemma is not clear. Immunofluorescent staining shows that 
expression of δSG glycan mutant N108Q and N284Q is similar to wild type δSG 
(Figure 3-3). Taking advantage of the extracellular C-terminus myc tag, live-cell 
staining allows monitoring of δSG protein arrival at the plasma membrane. 
Myocytes expressing glycan mutant δSG N108Q or N284Q showed marked 
antibody staining in live cell configuration indicating the δSG protein mutants 
localized to the sarcolemma similar to wild type δSG expressing cardiac 
myocytes (Figure 3-4). To quantify this trafficking, we scored populations of live 
cell labeled cardiac myocytes revealing that glycan deficient mutant δSG proteins 
N108Q and N284Q are detectable at the plasma membrane at comparable levels 
to wild type delta sarcoglycan (Figure 3-5A). High resolution imaging using 
confocal mircoscopty showed that  expressed wild type appears to localize 
predominantly to either end of  cardiac myocytes in locations that previously 
formed intercalated disks in the intact heart (Figure 3-4).  To quantify this 
distribution and targeting of delta sarcoglycan in normal and mutant cells, we 
analyzed cardiac myocytes by quantifying the lateral membrane and end 
membrane fluorescence in cardiac myocytes. There is not a statistically 
significant difference in the distribution of mutant N108Q or N284Q at the plasma 
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membrane compared to wild type δSG (Figure 3-5B), indicating that mutant 
N108Q or N248Q appear to spatially localize to similar locations in cardiac 
myocytes as compared to WT. 
Loss of glycosylation at residue 108 causes myocyte detachment during 
mechanical strain 
 The function of δSG and the sarcoglycans have not been well established. 
Previous work in our lab suggests that δSG may play a functional role in 
stabilizing the sarcolemma during mechanical events (Chapter 2). The 
mechanism for this stabilization remains a mystery but could work through the 
interaction of the DGC to laminin. Additionally the cytosolic tail of δSG has been 
shown to bind dystrophin in vitro110. Mutations in δSG may somehow affect this 
interaction with dystrophin. Whether δSG glycan residues are necessary for δSG 
protein interactions has not been established. Adhesion of cardiac myocytes to 
laminin is unaffected when δSG glycan mutant N108Q or N284Q are expressed 
(Figure 3-6). Oddly when cardiac myocytes are stretched for 24 hours cardiac 
myocytes expressing δSG glycan mutant N108Q show increased detachment 
from laminin compared to wild type δSG expressing cardiac myocytes (Figure 3-
6). Furthermore, the expression of δSG glycan mutant N108Q or N284Q does 
not alter sarcolemmal integrity or cell morphology when submitted to mechanical 





 The δSG protein appears critical for function of striated muscle. Until very 
recently the only functional understanding of δSG was the role it played in proper 
assembly and function of the sarcoglycan complex in total. Recent data from our 
lab has suggested that the δSG protein may play an active functional role in 
maintaining sarcolemmal stability during mechanical events (Chapter 2). The 
mechanism to this function is still unclear but any and all of three hypotheses is 
likely. 1) Delta sarcoglycan binds directly to some ligand in the extracellular 
matrix. 2) Delta sarcoglycan binds directly to dystrophin and/or utrophin within 
the cytosol. 3) Delta sarcoglycan binds directly to another member of the DGC 
acting similar to an anchor within the sarcolemma. How δSG may perform any 
and all of these actions is unclear. The N-linked glycans are obvious targets of 
investigation for δSG protein function given the role glycosylation plays in DGC 
adhesion to laminin via glycosylated αDG. Additionally, our previous work has 
suggested that adding ectopic glycan residues does not inhibit δSG trafficking to 
the plasma membrane as would be expected. Furthermore, it has been shown in 
εSG that a gain-of-glycosylation mutation can cause myoclonus dystonia126 
suggesting that N-glycans on the sarcoglycans may be more than simple 
chaperones through the secretory pathway. This study investigated whether N-
linked glycans in the extracellular domain are necessary for δSG function. These 
results show that δSG does undergo N-linked glycosylation at residues 108 and 
284 in cardiac myocytes. 199, 200Furthermore the glycan at residue 108 plays a 
role in DGC binding to laminin during mechanical events. The mechanism of this 
binding remains a mystery but suggests strongly that either δSG directly binds 
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laminin in some capacity or that δSG is necessary for a stable linkage of laminin 
to αDG. The absence of glycosylation at the putative residue 60 can be 
explained due to its close proximity to the transmembrane domain of delta 
sarcoglycan (residues 36-56, Figure 3-1A). Amino acids as far away as 12 
residues from transmembrane domains are not readily accessible to the 
oligosaccaryltranferase that imparts sugar residues to proteins within the ER199, 
200 inhibiting glycosylation of consensus sequence sites that fall within this 12 
residue threshold. Labeling δSG at the plasma membrane reveals that δSG 
proteins localize predominantly to regions at the plasma membrane 
corresponding to the intercalated discs in the intact myocardium. Loss of 
glycosylation at either residue 108 or 284 did not significantly alter the 
localization of δSG to the plasma membrane nor its spatial distribution to 
membrane compartments in cardiac myocytes. The enrichment at the 
intercalated discs suggests that δSG may be involved somehow in the ability of 
cardiac tissue to act as a functional syncitium. Although expressing glycosylation 
deficient δSG did not alter the preferred localization to the intercalated discs it is 
possible that loss of these glycan residues could also alter the function of δSG at 
this location of the plasma membrane.   
 There are a number of regions within δSG proposed as critical for 
sarcoglycan complex assembly or for trafficking to the plasma membrane. 
Truncation of δSG prior to the cysteine-rich motif is sufficient to cause a decrease 
of the sarcoglycan complex at the plasma membrane110, 154, 156. Additionally in 
COS-1 cells it was established that mutating the asparagine at residue 108 to a 
!
! 90!
lysine reduces δSG at the plasma membrane110. This suggests a possible role for 
glycosylation at residue 108 in membrane trafficking, but the change from an 
asparagine to a lysine may alter protein structure and/or interactions sufficient to 
explain the decrease in δSG at the plasma membrane. The alteration of the 
asparagine at residue 108 to a glutamine is a much less drastic change in overall 
protein properties but still ablates glycosylation at residue 108. These results 
show that δSG glycan mutant N108Q actually does localize to the plasma 
membrane in cardiac myocytes suggesting that N-linked glycosylation at residue 
108 has some other role in δSG protein function. It is possible, that N-linked 
glycosylation of δSG has tissue specific roles. This would explain the discrepancy 
between our findings in cardiac myocytes and previous data obtained in COS-1 
cells. Furthermore, δSG mutant R71T exhibits a gain-of-glycosylation and 
appears to cause DCM but not skeletal muscle dystrophy158 supporting the 
hypothesis that δSG function is slightly altered from skeletal muscle to cardiac 
muscle.  
 δSG glycan mutant N284Q also localizes normally to the plasma 
membrane suggesting that neither glycan residue at 108 or 284 alone is 
responsible for δSG processing through the secretory pathway. Unfortunately 
generation of δSG glycan mutant N108Q/N284Q proved difficult preventing 
investigation into loss of all the N-linked glycosylation within the extracellular 
domain of δSG. It may be that either glycan residue is capable of covering for 
loss of glycosylation at the other site. These results showing residue 284 is 
glycosylated on only 23 percent of δSG proteins suggest that glycosylation at 284 
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may only play a supporting role for δSG protein when processing through the 
secretory pathway is somehow disrupted. Another possible explanation is that 
δSG plays more than one functional role within cardiac myocytes and each 
glycan residue plays a different function. There is some evidence to suggest that 
δSG can form a tricomplex distinct from the normal tetrameric sarcoglycan 
subcomplex110, 128, 132. Additionally δSG has been shown to localize to the 
sarcoplasmic reticulum201 and associate with 16-kD vacuolar ATPase202. Taken 
together these results indicate that δSG may undergo alternate processing 
depending on the final destination or interactions of δSG within the cell. It is likely 
that the vast majority of δSG proteins are located at the lateral sarcolemma as a 
part of the tetrameric sarcoglycan complex. Targeting of δSG to the sarcoplasmic 
reticulum or formation of a trimeric sarcoglycan complex may be accomplished 
via differential glycosylation at resides 108 and 284. This could explain why 
residue 284 is not occupied on all δSG proteins.  
 It is attractive to hypothesize that alternative glycosylation on residue 284 
is responsible for differential protein trafficking or function, however there are 
also other explanations that have support from the literature and are related to 
the mechanistic nature of glycosylation. Residue 284 is only 5 amino acid 
residues removed from the C-terminal end of δSG. It has been shown that N-
linked glycosylation consensus sequences within 60 residues of the C-terminus 
are less efficiently glycosylated than consensus sequences greater than 60 
residues proximal to the C-terminus199, 203 suggesting this may be the mechanism 
for partial glycosylation of residue 284. Additionally, N-linked consensus 
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sequences containing threonine at the third residue of the consensus site can be 
glycosylated up to 40 times more efficiently than consensus sequences 
containing serine at the third residue204, 205. Together the presence of serine at 
residue 286 and the consensus sequence close proximity to the C-terminus are 
the likely explanation for inefficient glycosylation on residue 284.   
 Although ablating the N-glycan residue at 284 did not disturb cell adhesion 
to laminin similar to losing the N-glycan at residue 108, residue 284 may still be 
involved somehow in cell adhesion to the basal lamina. We only tested cell 
adhesion via DGC to laminin, but it is possible that adhesion to another ECM 
protein such as collagen would be affected by the loss of N-glycan on δSG 
residue 284. Furthermore, the functional role of each glycan residue could be 
tissue specific. Losing N-glycosylation at residue 284 may be more pathogenic in 
skeletal muscle or smooth muscle, whereas the N-glycan at residue 108 is more 
important for protein interactions within cardiac myocytes and the myocardium. 
Our previous data suggested that overall glycosylation of the δSG protein is 
slightly altered in smooth muscle compared to cardiac myocytes and L6 
myotubes (Chapter 2), supporting the idea that the functional role of δSG 
glycosylation is different for each tissue type. It is also entirely possible that δSG 
glycosylation is not relevant in DGC binding to laminin or the basal lamina, but 
that integrating δSG mutant N108Q into the DGC is disruptive to overall DGC 
stability. 
 These results are the first to suggest that glycosylation is relevant for δSG 
protein function beyond simple protein processing through the secretory 
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pathway. How loss of δSG N-glycan at residue 108 disrupts laminin adhesion is 
still unclear. Determining whether δSG directly binds laminin would go a long way 
in explaining both the function of δSG as well as the function of the sarcoglycan 
complex. Finally, it would be useful to explore whether N-glycan residues on δSG 
have a role in binding other ECM proteins.  
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Figure 3-1. Glycosylation deficient adenoviral vectors expressed in cardiac 
myocytes reveals that delta sarcoglycan undergoes N-linked glycosylation 
at residues 108 and 284 in cardiac myocytes. (A) The four δSG constructs 
used. The top construct is wild type δSG with all three putative N-linked 
glycosylation sites intact. Mutant constructs each have one of the three putative 
glycosylation sites ablated. Light gray box represents the transmembrane 
domain, green tridents are putative N-glycan residues (B) δSG mutant protein 
expression compared to wild type δSG in cardiac myocytes. (C) Relative 
expression levels of δSG protein show glycosylation occupancy at the N284 site 




Figure 3-2. Loss of glycosylation in delta sarcoglycan at residue 108 or 284 
in cardiac myocytes does not alter cell viability or DGC expression. (A) 
Expressing glycan mutant δSG proteins does not alter cardiac myocytes 
morphology or cell viability. Cell viability was assessed by scoring normal rod-
shaped cells. (B) Total expression of glycosylated alpha-dystroglycan (IIH6), 
beta-dystroglycan (βDG), and beta-sarcoglycan (βSG). Values are presented as 





Figure 3-3. Loss of glycosylation in delta sarcoglycan at residue 108 or 284 
in cardiac myocytes does not alter expression or localization of the delta 
sarcoglycan protein. Immunofluorescent staining of cardiac myocytes 
expressing wild type and glycan mutant δSG proteins. Cells were permeabilized 
and fixed. Red-anti myc, blue-DAPI. The red channel has been enhanced to 




Figure 3-4. N-glycan deficient mutant delta sarcoglycan N108Q and N284Q 
localize and insert to the plasma membrane with equal efficiency as wild 
type delta sarcoglycan. Live-cell labeling of cardiac myocytes expressing wild-
type and glycan mutant δSG proteins. Initial labeling with primary antibodies is 
performed in media using no permeabilization or fixation to identify only δSG 
proteins exposing the C-terminus myc tag on the extracellular side of the 





Figure 3-5. Loss of N-linked glycosylation does not alter delta sarcoglycan 
membrane localization or enrichment at the intercalated discs. (A) Scoring 
of delta sarcoglycan immunofluorescence at the plasma membrane. 
Glycosylation deficient mutants are labeled at the plasma membrane at 
comparable levels to wild type δSG  (n=4 rats). (B) Protein localization at the 
plasma membrane. Delta sarcoglycan predominantly localizes to the intercalated 
discs and loss of glycosylation at residue 108 or 284 does not alter this natural 




Figure 3-6. Loss of N-linked glycosylation on delta sarcoglycan residue 108 
causes myocyte detachment from laminin after mechanical strain. Cardiac 
myocytes adhered before and after stretch. (top) The difference in total cells 
(rods and rounds). (center) The difference in rod-shaped cells. (bottom) The 
difference in round-shaped cells. Change is calculated as the difference in cells 
counted after stretch and cells counted without stretch (stretch – no stretch = 




Figure 3-7. Expression of glycosylation deficient delta sarcoglycan mutant 
N108Q or N284Q in cardiac myocytes does not affect sarcolemmal stability. 
Fluorescently labeled cardiac myocytes after mechanical stretch. (top) The 
percentage of positively labeled rod-shaped cells. (bottom) The percentage of 
positively labeled round-shaped cells. Values are presented as a percentage of 




Conclusions and Future Directions 
 
Summary of Thesis Work 
 Mutations within the genes encoding protein members of the DGC not 
only cause devastating skeletal muscle dystrophy, but also frequently lead to 
development of fatal cardiomyopathy37, 38, 40, 73, 74, 156. The presentation and 
development of cardiomyopathy in dystrophy-associated mutations of the DGC 
are dependent upon the member of the DGC affected (for reference see Table 
1.1). DGC mutations may cause functional deficits and development of 
cardiomyopathy through disruption of either of two distinct connections. The first 
obligate connection is within the intracellular space where dystrophin functionally 
links the DGC to the cytoskeleton via F-actin26-28. The second obligate 
connection is on the extracellular face where glycosylated αDG binds to the 
basal lamina via laminin12-16. Defects within the DGC disrupting either or both of 
these links cause sarcolemmal instability allowing large extracellular molecules 
and ions such as Ca2+ to pass across the sarcolemma and into the cell when 
myocytes are mechanically strained63, 65-68 (Figure 1). The unregulated passage 
of extracellular ions likely causes a host of cellular dysfunctions especially due to 
the many signaling mechanisms involving Ca2+. Although glycosylated αDG and 
dystrophin are two key members of the DGC establishing these connections 
mutations in additional members of the DGC, notably the sarcoglycans, cause 
limb-girdle muscular dystrophy with concomitant sarcolemmal instability65. 
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Mutations within the extracellular domain of the δSG protein have also been 
linked to development of dilated cardiomyopathy157, 158. This suggests that δSG 
function is critical to DGC function beyond simply assembly of the overall 
complex. Mutations in the extracellular domain of δSG may affect one or both of 
the two obligate connections of the DGC stabilizing the sarcolemma in cardiac 
tissue. The critical nature of the δSG protein and its post-translational 
modifications in maintaining DGC stability was the basis for the experiments 
performed in chapter 2 and 3. These two chapters explored the physiological 
outcome when δSG mutants were expressed in isolated cardiac myocytes. It is 
not entirely clear in cardiac muscle whether the sarcolemma is simply more 
permeable when the DGC is disrupted or whether mechanical action is what 
causes membrane permeability. Overall, the experiments performed in this thesis 
were designed to determine the mechanism by which mutations in the protein 
δSG exert a dominant negative effect on cardiac myocyte function possibly 
leading to dilated cardiomyopathy. The experiments described in chapters 2 and 
3 and summarized hereafter support the overall hypothesis that dominant 
mutations in the extracellular domain of delta sarcoglycan alter protein structure 
or post-translational modifications directly causing DGC dysfunction and leading 
to disrupted mechanical stability of cardiac myocytes.  
 Chapter 2 described the functional and biochemical consequences of 
expressing DCM-linked δSG mutations in cardiac myocytes. Expression of 
mutant δSG R97Q or R71T is sufficient to cause sarcolemma instability during 
mechanical strain. Although previous work has suggested that DCM-linked δSG 
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mutants may primarily owe disease pathology to trafficking defects159, δSG 
mutant R97Q and R71T both localize and are stable at the sarcolemma. This 
suggests that, unlike LGMD2F causing recessive mutations, δSG mutants R97Q 
and R71T exert dominant negative effects on overall DGC function. Interestingly, 
when protein lysates from cardiac myocytes expressing δSG mutant R71T were 
run on western blot it revealed a strikingly different pattern of post-translational 
modification compared to wild type δSG. Treatments using endoglycosidases 
reveal the additional bands from mutant R71T to be alternatively glycosylated 
forms of δSG. The change in amino acid at residue 71 from an asparagine to a 
threonine forms a new consensus site for N-linked glycosylation. Whether the 
ectopic glycosylation at residue 71 is responsible for sarcolemma instability is 
unclear and led to investigation of the role glycan residues on δSG may play in 
δSG and overall DGC function.  
 To further investigate the role of glycan residues on δSG in protein 
function we generated adenovirus expressing mutants lacking the putative sites 
of N-linked glycosylation in δSG. Chapter 3 described the functional 
consequences of disrupting N-linked glycosylation on δSG. In ventricular muscle 
δSG appears to be N-glycosylated at only two of the putative sites in the 
extracellular domain; asparagine residues 108 and 284. Mutating δSG to ablate 
N-glycosylation at either of these two residues does not impact δSG protein 
localization and integration into the plasma membrane. Additionally expression of 
glycosylated alpha dystroglycan, beta dystroglycan, and beta sarcoglycan is 
unchanged when expressing N-glycan mutant δSG. These results indicate that 
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N-glycosylation of δSG is not responsible for protein trafficking through the 
secretory pathway in cardiac myocytes or assembly of the sarcoglycan complex 
as previously hypothesized from ectopic expression in non-muscle cell types. 
Exposing cardiac myocytes expressing N-glycan mutant δSG to mechanical 
stretch revealed no obvious sarcolemma instability. This was contrary to chapter 
2 data showing that aberrantly glycosylated δSG mutant R71T expression is 
sufficient to cause plasma membrane instability during mechanical strain. 
Interestingly, cardiac myocytes expressing δSG lacking glycosylation at 
glutamine residue 108 have increased detachment from laminin after mechanical 
stretch. Our results indicate that post-translational glycosylation on δSG may be 
necessary for DGC function at the plasma membrane during mechanical events 
in a way that more dramatically impacts overall cell adhesion. Importantly these 
results are the first to suggest that δSG may have a functional role in matrix 
adhesion during mechanical strain. 
 The most likely explanation for the discrepancy between phenotypes 
concerning ectopic glycosylation caused by mutant R71T and glycosylation 
deficiency caused by mutant N108Q relates to the relative location of each 
mutation. In COS-1 cells the residues from 57-92 are necessary for association 
and binding with βSG. Mutation of the arginine to threonine at residue 71 and 
subsequent ectopic glycosylation at residue 69 probably disturbs this interaction 
leading to disruption of sarcoglycan complex function. N-linked glycans that are 
sialyted also have a negative charge and its also possible that electrostatic 
interactions of the glycan near the membrane some how impacts delta 
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sarcoglycan protein structure, nearby membrane proteins or the membrane itself.  
Conversely the loss of glycosylation at residue 108 falls outside of the domain 
proposed for interaction with βSG and may be exposed more directly to the 
extracellular matrix.  This may explain why the N108Q δSG mutation affects 
myocardial cell adhesion in isolated cardiac myocytes.  
 It is difficult to infer much more from the spatial location of each mutation 
within δSG. The reason for this is that a number of disease causing 
polymorphisms within δSG are spatially in close proximity to one another  and yet 
can present with vastly different phenotypes, some with muscular dystrophy and 
some with dilated cardiomyopathy (for reference see figure 1-5). For example, 
the R71T mutation discovered by Tsubata et al. and examined in chapter 2 lies 
within the βSG interaction domain of δSG110 and is linked to DCM157. The 
LGMD2F causing G76C mutation112 resides only 5 residues from the R71T 
mutation and is also within the domain necessary for interaction with βSG. These 
two mutations are extremely close to each other and both reside in the same 
domain necessary for a specific protein interaction and yet cause two distinct 
phenotypes.  One appears to result in a null protein mutation (G76C), and based 
on my thesis data R71T would be predicted to have normal protein expression in 
patients but have dominant negative effects on δSG function. Furthermore, the  
domain between residues 93 and 262 contains 6 verified mutations causing 
either DCM or LGMD2F. This domain has not been implicated in any specific 
protein-protein interactions of δSG protein but is apparently essential for some 
aspects of protein function. It is possible that the domain from residues 93-262 is 
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responsible for interaction with one of the other sarcoglycans, dystroglycans, or 
other extracellular matrix ligands which could help explain why mutations in that 
region are pathogenic and cause DGC dysfunction but does not elucidate why 
mutations in this domain can cause disparate phenotypes.  
 One possible explanation for phenotypic dissimilarity of mutations in δSG 
relates to truncation of the protein as opposed to point mutants. The cysteine-rich 
motif in δSG has been implicated in proper localization to the plasma membrane 
of the sarcoglycan complex110. Two of the five known mutations causing 
LGMD2F are caused by truncation of δSG prior to the cysteine-rich motif and 
furthermore one other LGMD2F causing mutation is located immediately 
proximal to this motif. This suggests that disruption of the cysteine-rich motif may 
be a contributing factor to complete loss of protein stability, resulting in a null 
mutation, loss of delta sarcoglycan expression and development of LGMD2F as 
opposed to only DCM.  
 Delta sarcoglycan is not the only protein within the DGC that exhibits 
dissimilarity in phenotypes as a consequence of disease causing polymorphisms. 
Although Becker Muscular Dystrophy (BMD) is caused by mutations in the same 
dystrophin gene that causes Duchenne muscular dystrophy, patients with BMD 
have a remarkably heterogeneous presentation. Skeletal myopathy in BMD is 
normally not as severe as that observed in DMD206, 207. However, despite mild or 
no skeletal muscle weakness patients can present with severe 
cardiomyopathy208, 209.  
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It is also possible that the disparate phenotypic outcomes of different 
mutations within δSG relate more to differences in the physiology of cardiac 
muscle and skeletal muscle. Skeletal muscle is typically only recruited and 
activated in situations where it is needed to produce force. Skeletal muscles that 
are more active such as the muscles of the shoulders and those muscles used 
during ambulation in the hips and torso are far more affected by limb-girdle 
muscular dystrophy. In general in DMD/BMD patients and patients with other 
forms of muscular dystrophy such as sarcoglycanopathy or dystroglycanopathy, 
cardiac disease is more slowly progressive than skeletal disease. However, 
cardiac disease becomes highly penetrant in older individuals even in the 
presence of very mild skeletal muscle dysfunction or even as the first sign of 
disease individuals. In many cases heart disease can deterioriate to a level 
requiring cardiac transplant, even though the patient retains a high degree of 
skeletal muscle function supporting normal ambulation. One possibility is that  
the DCM linked δSG mutants R71T, R97Q, S151A, or ΔK238 may have fairly 
mild dysfunction leading to low or incomplete penetrance of DCM-linked δSG 
mutations such that skeletal muscle disease does not reach clinical significance 
but cardiac disease appears later in the patients lifespan as DCM. This may be 
similar to disease causing mutations in FKRP (a dystroglycanopathy) that first 
presented as cardiac disease in human patients with complete absence of 
skeletal muscle symptoms210-212. Indeed, work by Bauer et al. concluded that the 
S151A mutation in δSG previously linked to DCM may be a rare non-disease 
causing polymorophism153, but does not account for the possibility that the 
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S151A mutation may simply have reduced penetrance with respect to DCM. Also 
of note is the fact that sub-physiogical expression of the sarcoglycans in skeletal 
muscle from mdx mice appears to be mildly compensatory to dystrophic 
pathology213 suggesting that even low levels of functional sarcoglycans can help 
prevent development of skeletal muscle myopathy.  It is entirely probable that low 
penetrance of DCM-linked mutations of δSG coupled with expression of one 
functional copy of the δSG protein is sufficient to prevent skeletal muscle disease 
and may help explain the tissue specific effects of DCM-linked mutations in δSG  
 
Future Directions 
Mechano-Protection of the Sarcolemma by Delta Sarcoglycan in Cardiac 
Myocytes 
 In the dystrophin glycoprotein complex the sarcoglycans exist as a 
tetrameric subcomplex37, 40, 41, 88. Despite identification of the sarcoglycans in 
striated muscle almost 20 years ago37, 40, 41, 102, 105 very little is known about their 
function. The DGC performs the critical function at the lateral sarcolemma of 
mechanical protection during stretch and contraction59-63, 66. When the 
sarcoglycan complex is lost due to mutation or knockdown the sarcolemma 
becomes increasingly permeable to extracellular molecules and ions91, 97, 141-144. 
This originally led to the hypothesis that the sarcoglycan complex functionally 
stabilizes the DGC at the plasma membrane. The identification of DCM-linked 
mutations in δSG that do not cause apparent skeletal myopathy and do not result 
in complete loss of the sarcoglycan at the plasma membrane were some of the 
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first evidence to suggest that δSG may have a functional role outside of DGC 
assembly and/or stabilization157. The mechanism of these DCM-linked δSG 
mutations was unclear but subsequent study using transgenic mice 
overexpressing the S151A δSG mutation showed a trafficking defect concomitant 
with a loss of the sarcoglycan complex at the plasma membrane and disruption 
of nuclear membrane proteins159. The results in chapter 2 challenge this 
conclusion regarding the mechanism of action for DC mutants. There are three 
important limitations to the conclusions in chapter 2. 1) Identifying mutant δSG 
R97Q and R71T interactions with other sarcoglycans or members of the DGC 
proved difficult due to the limited amount of protein produced in the isolated 
cardiac myocyte model, 2) isolated cardiac myocytes are only stable in culture for 
a matter of days disallowing investigation into long-term expression of mutant 
δSG R97Q or R71T, and 3) sarcolemmal instability in isolated cardiac myocytes 
may not necessarily be recapitulated in vivo where cells are in 3-dimensional 
contact with the matrix. Because δSG mutant R97Q and R71T do not show a 
trafficking defect nor subsequent disruption of nuclear proteins similar to S151A it 
is reasonable to hypothesize that production of transgenic mice expressing these 
two mutants would not have the high lethality observed in transgenic mice 
overexpressing δSG mutant S151A.  
 Transgenic mice expressing δSG mutant R97Q and R71T would 
overcome the limitations of protein quantity and allow investigation into chronic 
expression of mutant δSG proteins in vivo. Co-immunoprecipitation experiments 
using pulldown of myc-tagged transgenic proteins would allow probing for 
!
! 110!
sarcoglycans, dystrophin, and dystroglycans proving finally that mutant δSG 
R97Q and R71T not only localize and insert into the plasma membrane but also 
associate and integrate tightly with the DGC. It would be predicted that δSG 
mutants fully integrate into the DGC in vivo at the sarcolemma and pulldown the 
remaining members of the DGC.  
 Transgenic mice would also allow evaluation of sarcolemmal integrity in 
vivo by injecting mice with Evan’s blue dye and stimulating the heart either 
pharmacologically with isoproterenol or via exercise using a treadmill. Given the 
sarcolemmal instability observed in mutant δSG expressing cardiac myocytes 
outlined in chapter 2 it should follow that sarcolemmal integrity is compromised in 
vivo causing an increase in Evan’s blue dye uptake that is likely exacerbated by 
cardiac stimulation. It should be noted that knock-in mice could be used rather 
than transgenic mice. Although generation of knock-in mice is significantly more 
time consuming and technically difficult a heterozygous knockin mouse for either 
R71T or R97Q would be the most accurate genetic representation of patients 
with δSG linked DCM. There is also an alternative to generating transgenic or 
knock-in mice if given a more limited timeframe. Mutant δSG R97Q or R71T 
could be engineered into AAV and injected into δSG knockout mice or the BIO 
14.6 hamster as previously performed by Holt et al214. AAV serotype 9 would be 
selected for its superior global cardiac gene transfer in rodents215. 
 There has been some evidence that calls into question whether 
dominantly inherited δSG dilated cardiomyopathy actually exists153. A study of a 
large consanguineous family containing both an A131P δSG mutation causing 
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LGMD2F and DCM-linked S151A δSG mutation showed no signs of development 
of cardiomyopathy even in the presence of heterozygous LGMD2F causing 
mutations. The study concluded that the S151A mutation doesn’t actually cause 
dominantly inherited DCM and questioned the role of other dominantly inherited 
δSG mutations in DCM pathology. There are crucial experiments that may 
silence lingering criticism about whether δSG mutants R97Q or R71T cause 
DCM despite the conclusions by Bauer et al. The δSG knockout mouse is a well-
characterized model of human LGMD2F. Hearts could be isolated from δSG 
knockout mice and transduced using adenoviral vectors expressing δSG mutant 
R97Q or R71T. Sarcolemmal integrity could easily be tested using modified 
stretch protocols similar to chapters 2 and 3. Delta sarcoglycan knockout mice 
could also be crossed to transgenic or knock-in mice expressing δSG mutant 
R97Q or R71T. Expression of mutant δSG R97Q or R71T in δSG deficient 
cardiac tissue would be predicted to not rescue the compromised membrane 
integrity in δSG deficient animals.  
 Despite the presence of sarcolemmal instability in cardiac myocytes 
expressing mutant δSG R97Q or R71T and a subsequent contracture of 
myocytes, the mechanism of this dysfunction is lacking. Previous studies have 
suggested that perturbation of the link between glycosylated alpha dystroglycan 
and the extracellular matrix are responsible for plasma membrane fragility180. 
Calcium influx through fragile membranes has been hypothesized as the initiating 
event for contracture and development of a dystrophic phenotype in both skeletal 
and cardiac muscle. It would further the understanding of dominant negative δSG 
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mutations to identify whether the phenotypes of sarcolemmal instability observed 
in chapter 2 are indeed caused by Ca2+ influx.  
 A previous study showed that inhibiting calcium influx through TRPC3 
channels in dystrophic skeletal muscle dramatically improved disease 
pathology216. One of the models in this study was a cross of the δSG knockout 
mouse to a transgenic mouse overexpressing a dominant negative TRPC3 
channel inhibitor using the human skeletal actin promoter. An adenovirus 
expressing the same dominant negative TRPC6 (dnTRPC6) using the 
cytomegalovirus promoter could easily be generated. Isolated cardiac myocytes 
from transgenic mice expressing δSG mutant R97Q or R71T transduced with 
adenovirus expressing dnTRPC6 allows investigation into the role of Ca2+ influx 
as an initiating event for cell contracture in vitro. For in vivo studies AAV9 
expressing dnTRPC6 could be injected into transgenic mice pups expressing 
R97Q and R71T and hearts from these mice could be examined for dystrophic 
pathology and Evan’s blue dye uptake.   
 Identifying how δSG mutants R97Q or R71T cause DGC dysfunction and 
ultimately dystrophic cardiomyopathy would further understanding of the 
mechanism of DGC disruption causing sarcolemmal instability. Previous studies 
have shown the N-terminal domain of alpha dystroglycan is cleaved and shed 
into human serum implicating this as a potential contributing factor to DGC 
dysfunction due to reduction of alpha dystroglycan at the plasma membrane 
acting as a high affinity laminin receptor217. Collecting serum from transgenic or 
knockin mice expressing δSG mutant R97Q or R71T and probing for the N-
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terminal of alpha dystroglycan could reveal whether the mechanism of 
sarcolemmal fragility is via a secondary alpha dystroglycanopathy. Shedding of 
alpha dystroglycan into the serum of R97Q or R71T transgenic or knockin mice 
would support the hypothesis that the sarcoglycan complex has a role in 
stabilizing the dystroglycans. Some studies have also identified beta 
dystroglycan cleavage via a matrix metalloprotease (MMP)135, 136. This has been 
proposed as a mechanism for DGC destabilization due to the fact that beta 
dystroglycan cleavage occurs in dystrophies where the sarcoglycan complex is 
absent. However, because mutant δSG R97Q and R71T are predicted to 
integrate and form a fully mature sarcoglycan complex it would not be 
hypothesized that beta dystroglycan would undergo proteolytic cleavage by this 
MMP. If it were established in transgenic mice expressing mutant δSG R97Q or 
R71T that sarcoglycan trafficking and assembly is unperturbed yet beta 
dystroglycan still undergoes proteolytic cleavage it can be assumed that the 
sarcoglycan complex is not responsible for spatially inhibiting access to the 
cleavage site on beta dystroglycan, but is instead involved in some other 
mechanism of proteolytic cleavage inhibition.  
 
Delta Sarcoglycan function in Extracellular Matrix Adhesion 
 The data presented in chapter 3 suggests that in addition to having a role 
in mechano-protection δSG may also play a role in adhesion to the extracellular 
matrix. These are not the first results to implicate the sarcoglycans in cell matrix 
adhesion218, 219. Previous work by Yoshida et al discovered that pulldown of 
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alpha sarcoglycan or dystrophin in L6 myotubes includes co-immunoprecipitation 
of α5β1 integrin and focal adhesion proteins vinculin, talin, and paxillin. Integrin α5 
is a receptor for fibronectin and is upregulated in dystrophic muscle. Anti-sense 
oligomers directed against alpha and gamma sarcoglycan cause reduction in 
focal adhesion proteins and a significant reduction in cell adhesion. Additionally, 
adhesion of L6 myotubes to collagen or fibronectin results in tyrosine 
phosphorylation on alpha and gamma sarcoglycan. The authors concluded that 
there exists a system of bidirectional signaling between the sarcoglycan complex 
and the integrins during cell adhesion. Notably, the authors did not examine δSG 
using their model. Due to the necessity of the sarcoglycan complex to be 
expressed as a unit it is likely that pulldown of δSG would also co-
immunoprecipitate α5β1 integrin and focal adhesion proteins.  
 Delta sarcoglycan mutant N108Q described in chapter 3 revealed that 
glycosylation on residue 108 appears to play a role in myocyte adhesion to 
laminin. These results are distinct from hypoglycosylated alpha dystroglycan cells 
that show no apparent defect in cell adhesion180. Two critical experiments can be 
performed to determine if ablation of N-glycosylation at residue 108 in δSG 
affects the α5β1 integrin adhesion system. The first is using fibronectin as a 
matrix substrate for culturing and stretching cardiac myocytes. Fibronectin is 
bound by α5 integrins but not alpha dystroglycan so if the contribution of δSG to 
ECM adhesion is not laminin specific it would be expected that we would obtain 
similar results using fibronectin as the results reported in chapter 3. The second 
crucial experiment is pulling down wild type and mutant δSG N108Q and 
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examining for co-immunoprecipitation with α5β1 integrin and other focal adhesion 
proteins. It would be expected that if myocyte adhesion is reduced through the 
α5β1 integrin system that pulldown of glycan deficient δSG mutant N108Q would 
show reduced or no co-immunoprecipitation with focal adhesion proteins 
compared to wild type δSG. It should be noted that attempting to perform this 
experiment in isolated cardiac myocytes could prove difficult due to limitations in 
total protein making co-immunoprecipitation experiments troublesome. To 
overcome this it is would be necessary to use the adenoviral vectors described in 
chapter 3 in a different cellular model such as COS or CHO cells. Neither of 
these cell lines model cardiac tissue however, so it would be more relevant to 
use either HL-1 cells or a transgenic mouse expressing glycan mutant δSG 
N108Q.  
 In addition to bidirectional signaling between the integrins and 
sarcoglycans it has been suggested that upregulation of α7β1 integrin can 
compensate for loss of the sarcoglycan complex in dystrophic muscle. This is 
supported by data showing upregulation of α7 integrin in the muscle of δSG and 
γSG knockout mice218. Additionally, mice knocked out for both α7 integrin and 
gamma sarcoglycan showed marked increase in dystrophy and a subsequent 
decrease in sarcolemmal stability218. A separate study identified that transgenic 
overexpression of α7 integrin reduces cardiomyopathy in dystrophic mice220. 
Together these data suggest that the integrin system of cell adhesion works in 
parallel with the DGC to maintain sarcolemmal integrity and cell adhesion to the 
extracellular matrix. The data in chapter 3 suggesting myocyte adhesion to 
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laminin is decreased in cardiac myocytes expressing δSG mutant N108Q does 
not address whether this adhesion defect is mediated through dystroglycan or 
the integrins. Our lab has generated a transgenic mouse overexpressing the 
glycosyltransferase LARGE driven by the MCK promoter. This results in 
hyperglycosylation of alpha dystroglycan and increased laminin binding. Cardiac 
myocytes isolated from this transgenic model and transduced using the 
adenoviral vectors described in chapter 3 can be stretched and observed for 
myocyte detachment. If decreased cell adhesion from expression of N-glycan 
mutant δSG is mediated through the integrins it would be predicted that 
overexpression of LARGE would partially or fully rescue this phenotype. 
Conversely, if rescue does not occur we can perform the same test in transgenic 
mice overexpressing α7 integrin220. If decreased cell adhesion from expression of 
δSG mutant N108Q is mediated through the DGC it would be predicted that 
overexpression of α7 integrin would partially or fully rescue this phenotype.  
 Data in chapter 3 reveals an adhesion defect but it lacks an explanation. 
Glycosylation residues on delta sarcoglycan may destabilize the sarcoglycan 
complex resulting in dissociation from the sarcolemma. To further investigate the 
role of δSG in myocyte attachment to laminin through alpha dystroglycan it would 
be useful to examine protein-protein interactions within the DGC that may be 
disturbed when δSG mutant N108Q is expressed. Previous studies have 
performed co-immunoprecipitation using increasingly stringent conditions to 
identify which interactions are the weakest among the sarcoglycans and 
dystroglycans128, 221. These experiments can be performed in transgenic mice 
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overexpressing δSG N108Q to identify whether loss of glycosylation at δSG 
residue 108 causes decreased interaction of δSG with any of the other members 
of the DGC.  
 As described in the previous section cleavage of alpha dystroglycan or 
beta dystroglycan has been proposed as a mechanism for DGC dysfunction. The 
decrease in adhesion when δSG N108Q is expressed may be due to an 
increased cleavage of either of these two proteins. Collecting the media from 
stretched cardiac myocytes expressing δSG N108Q and analyzing for either 
alpha dystroglycan or beta dystroglycan released into the media would help 
explain decreased adhesion to laminin after mechanical strain especially if this 
phenotype is mediated via DGC rather than integrin adhesion to laminin.  
 
Conclusions 
 The results described in this dissertation reveal that δSG contributes 
directly to sarcolemmal stability during mechanical events. Importantly this work 
demonstrates the DCM-linked mutations in δSG have a dominant negative effect 
on overall DGC function. Importantly it also demonstrates that the N-glycan at 
residue 108 in δSG contributes to protein function in a manner that appears 
distinct from δSG DCM mutations and other DGC mutations. These are the first 
data to reveal a functional role for N-linked glycosylation of δSG beyond simple 
sarcoglycan assembly or expression. Additionally these data reveal a functional 
role for δSG in cell adhesion that has not previously been proposed.  
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 Prior to this study investigation into the functional role of δSG has proved 
difficult due to the fact that many mutations in δSG behave as nulls and 
destabilize the entire sarcoglycan complex. With the exception of a few signaling 
mechanisms individual function of any sarcoglycan has not been identified. Given 
the nature of myocyte detachment from laminin in cardiac myocytes expressing 
δSG mutant N108Q it is intriguing to propose that δSG may bind directly to 
laminin or other matrix ligands. Mutations in δSG that alter its extracellular 
domain structure or post-translational modification likely exert their effects 
through dystroglycans but may also influence other matrix receptors or directly 
contribute to matrix binding. Elucidating these alternative mechanisms may 
reveal important new functions for δSG that are DGC independent and these new 
mechanisms may be important for therapeutic intervention. In the future 
treatments targeted to rescuing or enhancing δSG function at the sarcolemma in 






Figure 4-1. Sarcolemma integrity is disrupted in mutations of the DGC 
proteins and exacerbated by mechanical strain. The DGC forms a functional 
linkage between the cytoskeleton in striated muscle and basal lamina. Disruption 
of the DGC causes micro-tears in the sarcolemma during mechanical cycles of 
stretch or contraction allowing unregulated passage of extracellular molecules 




Figure 4-2. Delta sarcoglycan may mediate cell adhesion to laminin through 
the integrins or DGC. Bidirectional signaling and association with the integrins 
suggests that the sarcoglycan complex supports cell adhesion to laminin through 
multiple systems. Glycosylation on residue 108 in delta sarcoglycan may confer a 
specific protein interaction aiding one or both of these systems during 
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